WO1992014138A1 - Method and apparatus for magnetic microparticulate based luminescence assay including plurality of magnets - Google Patents
Method and apparatus for magnetic microparticulate based luminescence assay including plurality of magnets Download PDFInfo
- Publication number
- WO1992014138A1 WO1992014138A1 PCT/US1992/000982 US9200982W WO9214138A1 WO 1992014138 A1 WO1992014138 A1 WO 1992014138A1 US 9200982 W US9200982 W US 9200982W WO 9214138 A1 WO9214138 A1 WO 9214138A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- assay
- electrode
- particles
- ecl
- analyte
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6816—Hybridisation assays characterised by the detection means
- C12Q1/6825—Nucleic acid detection involving sensors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/66—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light electrically excited, e.g. electroluminescence
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/75—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated
- G01N21/76—Chemiluminescence; Bioluminescence
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
- G01N33/54326—Magnetic particles
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54366—Apparatus specially adapted for solid-phase testing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54366—Apparatus specially adapted for solid-phase testing
- G01N33/54373—Apparatus specially adapted for solid-phase testing involving physiochemical end-point determination, e.g. wave-guides, FETS, gratings
- G01N33/5438—Electrodes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
- G01N1/40—Concentrating samples
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2458/00—Labels used in chemical analysis of biological material
- G01N2458/30—Electrochemically active labels
Definitions
- This invention relates to a method for performing a binding assay for an analyte of interest present in a sample based upon measurement of electroche iluminescence at an electrode wherein a complex including the sample, an assay-performance substance containing a component linked to a label capable of being induced to electrochemiluminesce, and a plurality of magnetically responsive suspended particles capable of binding with the analyte or substance is formed; the complex is collected at the surface of an electrode by the imposition of a magnetic field on the particles by a plurality of permanent magnets or electromagnets in north-south orientation; the label is induced to luminesce; and, the luminescence emitted is measured.
- the invention also relates to apparatus for performing such a method having the plurality of permanent magnets or electromagnets in north-south orientation.
- Photoluminescence is the process whereby a material is induced to luminesce when it absorbs electromagnetic radiation. Fluorescence and phosphorescence are types of photoluminescence.
- Cyhemiluminescent processes entail the creation of luminescent species by chemical transfer of energy.
- “Electrochemiluminescence” entails creation of luminescent species electrochemically.
- Chemiluminescent assay techniques where a sample containing an analyte of interest is mixed with a reactant labeled with a chemiluminescent label have been developed. The reactive mixture is incubated and some portion of the labeled reactant binds to the analyte. After incubation, the bound and unbound fractions of the mixture are separated and the concentration of the label in either or both fractions can be determined by chemiluminescent techniques. The level of chemiluminescence determined in one or both fractions indicates the amount of analyte of interest in the biological sample. Electrochemiluminescent (ECL) assay techniques are an improvement on chemiluminescent techniques.
- ECL Electrochemiluminescent
- U.S. Patent No. 4,305,925 relates to the detection and determination of clinically relevant proteins and peptides by means of nephelometric and tur- bidi etric methods. The methods disclosed involve binding the antigen or antibody to latex particles which perform the function of light scattering or adsorption.
- U.S. Patent No. 4,480,042 relates to techniques employing particle reagents consisting of shell-core particles. The shell contains functional groups to which compounds of biological interest can be covalently bonded, and the high refractive index of the core results in high sensitivity to light scattering measurements.
- U.S. Application Serial No. 539,389 (PCT published application U.S. 89/04919) teaches sensitive, specific binding assay methods based on a luminescent phenomenon wherein inert microparticulate matter is specifically bound to one of the binding reactants of the assay system.
- the assays may be performed in a heterogeneous (one or more separation steps) assay format and may be used most advantageously in a homogeneous (nonseparation) assay format.
- U.S. 89/04919 relates to a composition for an assay based upon a binding reaction for the measurement of luminescent phenomenon, which composition includes a plurality of suspended particles having a surface capable of binding to a component of the assay mixture.
- it is directed to a system for detecting or quantitating an analyte of interest in a sample, which system is capable of conducting the assay methods using the assay compositions of the inventions.
- the system includes means for inducing the label compound in the assay medium to luminesce, and means for measuring the luminescence to detect the presence of the analyte of interest in the sample.
- U.S. 89/04919 is directed to methods for the detection of an analyte of interest in a sample, which method includes the steps of (1) forming a composition comprising (a) a sample suspected of containing an analyte of interest, (b) an assay- performance-substance selected from the group consisting of (i) analyte of interest or analog of the analyte of interest, (ii) a binding partner of the analyte of interest or its said analog, and (iii) a reactive component capable of binding with (i) or (ii) , wherein one of said substances is linked to a label compound having a chemical moiety capable of being induced to luminesce, and (c) a plurality of suspended particles capable of specifically binding with the analyte and/or a substance defined in (b) (i) , (ii) , or (iii) ; (2) incubating the composition to form a complex which includes a particle and said label compound; (3) incuba
- Analogs of the analyte of interest which may be natural or synthetic, are compounds which have binding properties comparable to the analyte, but include compounds of higher or lower binding capability as well. Binding partners suitable for use in the present invention are well-known. Examples are antibodies, enzymes, nucleic acids, lectins, cofactors and receptors.
- the reactive components capable of binding with the analyte or its analog and/or with a binding partner thereof may be a second antibody or a protein such as Protein A or Protein G or may be avidin or biotin or
- SUBSTITUTE SHEET another component known in the art to enter into binding reactions.
- the luminescence arises from electrochemiluminescence (ECL) induced by exposing the label compound, whether bound or unbound to specific binding partners, to a voltammetric working electrode.
- ECL electrochemiluminescence
- the ECL reactive mixture is controllably triggered to emit light by a voltage impressed on the working electrode at a particular time and in a particular manner to generate light.
- the emission of visible light is an advantageous feature the composition or system may emit other types of electromagnetic radiation, such as infrared or ultraviolet light, X-rays, microwaves, etc.
- Use of the terms "electrochemiluminescence,” “electrochemiluminescent,” “luminescence,” “luminescent,” and “luminesce” includes the emission of light and other forms of electromagnetic radiation.
- the probability of the tunneling phenomenon falls off exponentially as the distance between the two species increases.
- the probability of the tunneling phenomenon occurring between two species is fairly high if the distance is less than 25 Angstroms (2.5 nm) but is fairly low if the distance is greater.
- the distance of 25 A is a rule-of-thumb used by those skilled in the art but is not an absolute limitation.
- ECL moiety "metal-containing ECL moiety” "label,” “label compound,” and “label substance,” are used interchangeably. It is within the scope of the invention for the species termed “ECL moiety,” “metal- containing ECL moiety,” “organo-metallic,” “metal chelate,” “transition metal chelate” “rare earth metal chelate,” “label compound,” “label substance” and “label” to be linked to molecules such as an analyte or an analog thereof, a binding partner of the analyte or an analog thereof, and further binding partners of such aforementioned binding partner, or a reactive component capable of binding with the analyte, an analog thereof or a binding partner as mentioned above.
- the above- mentioned species can also be linked to a combination of one or more binding partners and/or one or more reactive components. Additionally, the aforementioned species can also be linked to an analyte or its analog bound to a binding partner, a reactive component, or a combination of one or more binding partners and/or one or more reactive components. It is also within the scope of the invention for a plurality of the aforementioned species to be bound directly, or through other molecules as discussed above, to an analyte or its analog. For purposes of brevity, these ligands are referred to as an assay-performance-substance.
- collection and concentration of complex may be used interchangeably to describe the concentration of complex within the assay composition and the collection of complex at, e.g., an electrode surface.
- Figs. 1 and 2 show the cell and plurality of magnets for performing the magnetic microparticulate- based separation or non-separation assay method of the invention; the plurality of magnets of the magnet system imposes field lines which are largely parallel to the plane of the electrode surface.
- Fig. 3 is a schematic representation of a sedimentation assay cell which employs electromagnets of Figs. 1 and 2 to cause the complex to settle on the electrode surface.
- Fig. 4 is a graph showing the relative rates of settling of microparticulate complex under the influence of a magnetic field (Figs. 1 and 2) and of gravity, respectively, i.e., a comparison of microparticulate settling times between a magnetic field (Figs. 1, 2) induced settling and gravity settling wherein values for the magnetic field settling are represented by open circles and the values for gravity settling are represented by darkened circles.
- Fig. 5 is a schematic representation of a collection cell including a permanent magnets of Figs. 1 and 2.
- Fig. 6 is a graph showing the increase in ECL intensity as a function of time in assays conducted with the cell of Fig. 5, i.e., the effect of collection time on ECL intensity.
- Fig. 7 is a schematic representation of the lines of force in the vicinity of the electrode surface of the magnets (Figs. 1 and 2) beneath the electrode surface.
- Fig. 8 is a schematic drawing of a cell for performing the microparticulate-based nonseparation and separation assays of the invention; the cell employs a working electrode and plurality of magnets as in Figs. 1 and 2.
- Fig. 9 is a simplified diagram of a voltage control apparatus for use with the cell of Fig. 8.
- the invention is in a method for performing a binding assay for an analyte of interest present in a sample.
- the steps include: (a) forming a composition containing (i) said sample (ii) an assay-performance-substance which contains a component linked to a label compound capable of being
- the invention also provides an apparatus for performing a binding assay for an analyte of interest present in a sample based upon measurement of electrochemiluminescence at an electrode surface comprising:
- SUBSTITUTE SHEET means for obtaining an even distribution of complex includes means for generating a magnetic field oriented with respect to said electrode so that the lines of force of said magnetic field are substantially parallel with the surface of said electrode in the region of said surface; and the means for generating a magnetic field includes a plurality of magnets in north-south orientation and separated by non-magnetic material positioned vertically below said electrode.
- Several different heterogeneous and homogeneous formats for binding assays can be implemented using the method described above to collect and concentrate the complex on the surface of an electrode. In a heterogeneous binding assay the complex is separated from the composition before measuring luminescence from the label. In homogeneous assays, no separation of the bound (to the solid phase) and unbound labeled reagents is made.
- the measured signal from the label is much greater than it would be in the absence of a collection step.
- the signal from the uncomplexed labeled reagents in contrast, is not changed.
- the signal from the collected complex is stronger than in an assay without collection of complex.
- the detection limit for the binding assay is, much improved as a result of the collection procedure.
- an in-situ separation step can be included in the homogeneous binding assay procedure.
- a second fluid is pumped through the cell which is free of label or labeled reagents, thereby performing an in-situ wash or
- SUBSTITUTE SHEET separation of the complex from unbound components of the assay composition is technically a heterogeneous binding assay.
- the ability to perform the separation inside the measurement cell is advantageous in that it does not require additional separation apparatus and the procedure is generally much faster than external separation methods.
- Heterogeneous binding assays are conducted using the invention by mixing the components of the assay composition and allowing them to react for a predetermined length of time.
- the assay composition is then subjected to a separation step wherein the solution is separated from the particles .
- Electrochemiluminescence is then measured from either the complex or the solution. Measuring the ECL from the complex after a concentration step permits measurement of analyte with better accuracy and with a lower detection limit than is possible without concentration.
- the invention is broadly applicable to analytes of interest which are capable of entering into binding reactions. These reactions include, e.g., antigen- antibody, ligand receptor, DNA and RNA interactions, and other known reactions.
- the invention relates to a method and apparatus for qualitatively and quantitatively detecting the presence of such analytes of interest in a multicomponent sample; the method and apparatus involve a plurality of north-south magnets.
- the Samples which may contain the analyte of interest, which may be in solid, emulsion, suspension, liquid, or gas form, may be derived from, for example.
- the sample may further comprise, for example, water, acetonitrile, dimethyl sulfoxide, dimethyl formamide, n-methyl-pyrrolidone or alcohols or mixtures thereof.
- Typical analytes of interest are a whole cell or surface antigen, subcellular particle, virus, prion, viroid, antibody, antigen, hapten, fatty acid, nucleic acid, protein, lipoprotein, polysaccharide, lipopolysaccharide, glycoprotein, peptide, polypeptide, cellular metabolite, hormone, pharmacological agent, synthetic organic molecule, organometallic molecule, tranquilizer, barbiturate, alkaloid, steroid, vitamin, amino acid, sugar, lectin, recombinant or derived protein, biotin, avidin, streptavidin, or inorganic molecule present in the sample.
- the analyte of interest is present at a concentration of 10 ⁇ 3 molar or less, for example, as low as 10 ⁇ 12 molar or lower.
- the assay-performance-substance which is combined with the sample containing the analyte of interest contains at least one substance selected from the group consisting of (i) added analyte of interest or its analog, as defined above, (ii) a binding partner of the analyte of interest or its said analog, and (iii) a reactive component, as defined above, capable of binding with (i) or (ii) , wherein one of said substances is linked to a compound or moiety, e.g. an ECL moiety capable of being induced to luminesce.
- a compound or moiety e.g. an ECL moiety capable of being induced to luminesce.
- the labeled substance may be a whole cell or surface antigen, a subcellular particle, virus, prion, viroid, antibody, antigen, hapten, lipid, fatty acid, nucleic acid, polysaccharide, protein, lipoprotein, lipopolysaccharide, glycoprotein, peptide, polypeptide, cellular metabolite, hormone, pharmacological agent, tranquilizer, barbiturate, alkaloid, steroid, vitamin, amino acid, sugar, nonbiological polymer (preferably soluble) , lectin, recombinant or derived protein, synthetic organic molecule, organometallic molecule, inorganic molecule, biotin, avidin or streptavidin.
- the reagent is an electrochemiluminescent moiety conjugated to an antibody, antigen, nucleic acid, hapten, small nucleotide sequence, oligomer, ligand, enzyme, or biotin, avidin, streptavidin. Protein A, Protein G, or complexes thereof, or other secondary binding partner capable of binding to a primary binding partner through protein interactions.
- Analogs of the analyte of interest are typically compounds which have binding properties comparable to the analyte, but can also be compounds of higher or lower binding capability.
- the reactive component capable of binding with the analyte or its analog, and/or with a binding partner thereof, and through which the ECL moiety can be linked to the analyte is suitably a second antibody or a protein such as Protein A or Protein G, or avidin or biotin or another component known in the art to enter into binding reactions.
- the Labels are metal chelates.
- the metal of that chelate is suitably any metal such that the metal chelate will luminesce under the electrochemical conditions which are imposed on the reaction system in question.
- the metal of such metal chelates is, for instance, a transition metal (such as a d-block transition metal) or a rare earth metal.
- the metal is preferably ruthenium, osmium, rhenium, iridium, rhodium, platinum, indium, palladium, molybdenum, tech- netium, copper, chromium or tungsten. Especially preferred are ruthenium and osmium.
- the ligands which are linked to the metal in such chelates are usually heterocyclic or organic in
- the ligands can be polydentate, and can be substituted.
- Polydentate ligands include aromatic and aliphatic ligands.
- Suitable aromatic polydentate ligands include aromatic heterocyclic ligands.
- Preferred aromatic heterocyclic ligands are nitrogen-containing, such as, for example, bipyridyl, bipyrazyl, terpyridyl, and phenanthrolyl.
- Suitable substituents include for example, alkyl, substituted alkyl, aryl, substituted aryl, aralkyl, substituted aralkyl, carboxylate, carboxaldehyde, carboxamide, cyano, amino, hydroxy, imino, hydroxycarbonyl, aminocarbonyl, amidine, guanidinium, ureide, sulfur-containing groups, phosphorus containing groups, and the carboxylate ester of N-hydroxy- succinimide.
- the chelate may have one or more monodentate ligands, a wide variety of which are known to the art. Suitable monodentate ligands include, for example, carbon monoxide, cyanides, isocyanides, halides, and aliphatic, aromatic and heterocyclic phosphines, amines, stilbenes, and arsines.
- Suitable chelates are bis [(4,4'- carbomethoxy)-2,2'-bipyridine] 2-[3-(4-methyl-2,2'-bi- pyridine-4-yl)propyl]-l,3-dioxolane ruthenium (II); bis (2,2'bipyridine) [4-(butan-1-al)-4'-methyl-2,2'-bi ⁇ pyridine] ruthenium (II) ; bis (2,2'-bipyridine) [4-(4'- methyl-2,2'-bipyridine-4'-yl)-butyric acid] ruthenium (II); tris (2,2'bipyridine) ruthenium (II); (2,2'- bipyridine) [bis-bis(l,2-diphenylphosphino)ethylene] 2- [3-(4-methyl-2,2'-bipyridine-4'-yl) ropyl]-1,3-dioxo
- ECL moieties The function of the ECL moieties is to emit electromagnetic radiation as a result of introduction into the reaction system of electrochemical energy. In order to do this, they must be capable of being stimulated to an excited energy state and also capable of emitting electromagnetic radiation, such as a photon of light, upon descending from that excited state. While not wishing to be bound by theoretical analysis of the mechanism of the ECL moiety's participation in the elec ⁇ trochemiluminescent reaction, we believe that it is oxidized by the introduction of electrochemical energy into the reaction system and then, through interaction with a reductant present in the system, is converted to the excited state. This state is relatively unstable, and the metal chelate quickly descends to a more stable state. In so doing, the chelate gives off electromagnetic radiation, such as a photon of light, which is detectable.
- the amount of metal chelate or other metal- containing ECL moiety incorporated in accordance with the invention will vary from system to system. Generally, the amount of such moiety utilized is that amount which is effective to result in the emission of a detectable, and if desired, quantitatable , emission of electromagnetic energy, from the aforementioned composition or system.
- the detection and/or quantitation of an analyte of interest is typically made from a comparison of the luminescence from a sample containing an analyte of interest and an ECL moiety to the luminescence emitted by a calibration standard developed with known amounts of the analyte of interest and ECL moiety. This assumes a homogeneous format. In the heterogeneous mode, a separation as discussed previously is carried out prior to ECL analysis.
- the particles advantageously comprise micro ⁇ particulate matter having a diameter of 0.001 to 200 ⁇ m, such as 0.05 ⁇ m to 200 ⁇ m, preferably 0.1 ⁇ m to 100 ⁇ m, most preferably 0.5 ⁇ m to 10 ⁇ m, and a surface component capable of binding to the analyte and/or one or more of the other substances defined above.
- the microparticulate matter may be crosslinked starch, dextrans, cellulose, proteins, organic polymers, styrene copolymer such as styrene/butadiene copolymer, acrylonitrile/butadiene/styrene copolymer, vinylacetyl acrylate copolymer, or vinyl chloride/aerylate copolymer, inert inorganic particles, chromium dioxide, oxides of iron, silica, silica mixtures, and proteinaceous matter, or mixtures thereof.
- the particles are suspended in the ECL system. However, the particles must be or must include magnetically responsive particles.
- the electrolyte is a phase through which charge is carried by ions.
- the electrolyte is in the liquid phase, and is a solution of one or more salts or other species in water, an organic liquid or mixture of organic liquids, or a mixture of water and one or more organic liquids.
- other forms of electrolyte are also useful in certain embodiments of the invention.
- the electrolyte may be a dispersion of one or more substances in a fluid —e.g., a liquid, a vapor, or a supercritical fluid —or may be a solution of one or more substances in a solid, a vapor or supercritical fluid.
- a fluid e.g., a liquid, a vapor, or a supercritical fluid
- the electrolyte is suitably a solution of a salt in water.
- the salt can be a sodium salt or a potassium salt preferably, but incorporation of other cations is also suitable in certain embodiments, as long as the cation does not interfere with the electrochemiluminescent interaction sequence.
- the salt's anion may be a phosphate, for example, but the use of other anions is also permissible in certain embodiments of the invention —once again, as long as the selected anion does not interfere with the electrochemiluminescent interaction sequence.
- the composition may also be nonaqueous. While supercritical fluids can in certain instances be employed advantageously, it is more typical to utilize an electro ⁇ lyte comprising an organic liquid in a nonaqueous composition. Like an aqueous electrolyte, the nonaqueous electrolyte is also a phase through which charge is carried by ions. Normally, this means that a salt is dissolved in the organic liquid medium. Examples of suitable organic liquids are acetonitrile, dimethylsulfoxide (DMSO) , dimethylformamide (DMF) , methanol, ethanol, and mixtures of two or more of the foregoing. Illustratively, tetraalkylammonium salts, such as tetrabutyla monium tetrafluoroborate, which are soluble in organic liquids can be used with them to form nonaqueous electrolytes.
- DMSO dimethylsulfoxide
- DMF dimethylformamide
- methanol ethanol
- ethanol ethanol
- the electrolyte is, in certain embodiments of the invention, a buffered system.
- Phosphate buffers are often advantageous. Examples are an aqueous solution of sodium phosphate/sodium chloride, and an aqueous solution of sodium phosphate/sodium fluoride.
- a reductant typically an amine or a ine moiety (of a larger molecule) which can be oxidized and spontaneously decomposed to convert it into a highly reducing species. It is believed that the amine or amine moiety is also oxidized by electrochemical energy introduced into the reaction system. The amine or amine moiety loses one electron, and then deprotonates, or rearranges itself, into a strong reducing agent. This agent interacts with the oxidized metal-containing ECL moiety and causes it to assume the excited state discussed above.
- a reductant typically an amine or a ine moiety (of a larger molecule) which can be oxidized and spontaneously decomposed to convert it into a highly reducing species. It is believed that the amine or amine moiety is also oxidized by electrochemical energy introduced into the reaction system. The amine or amine moiety loses one electron, and then deprotonates, or rearranges itself, into a strong reducing agent. This agent interacts with the oxidized
- the amine or amine moiety preferably has a carbon-centered radical with an electron which can be donated from such carbon, and an alpha carbon which can then act as a proton donor during deprotonation in order to form the reductant.
- the amine-derived reductant provides the necessary stimulus for converting the metal-containing ECL moiety to its excited state, from which detectable electromagnetic radiation is emitted.
- amines and corresponding amine moieties can be utilized in practicing the present inven ⁇ tion.
- the amine or amine moiety is chosen to suit the pH of the system which is to be electrochemiluminescently analyzed.
- Another relevant factor is that the amine or amine moiety should be compatible with the environment in which it must function during analysis, i.e., compatible with an aqueous or nonaqueous environment, as the case may be.
- the amine or amine moiety selected should form an amine-derived reductant under prevailing conditions which is strong enough to reduce the oxidized metal-containing ECL moiety in the system.
- Amines (and corresponding moieties derived therefrom) which are advantageously utilized in the present invention are aliphatic amines, such as primary, secondary and tertiary alkyl amines, the alkyl groups of each having from one to three carbon atoms, as well as substituted aliphatic amines.
- Tripropyl amine is an especially preferred amine as it leads to, comparatively speaking, a particularly high-intensity emission of electromagnetic radiation, which enhances the sensitivity and accuracy of detection and quantitation with embodiments in which it is used.
- diamines such as hydrazine
- polymines such as poly(ethyleneimine) .
- Examples of other amines suitable for practicing the invention are triethanol amine, triethyl amine, l,4-diazabicyclo-(2.2.2)-octane, 1- piperidine ethanol, l,4-piperazine-bis-(ethane-sulfonic acid), tri-isopropyl amine and poly(ethyleneimine) .
- the metal-containing ECL moiety utilized in the present invention is the reaction- limiting constituent. Accordingly, it is also typical that the amine or amine moiety is provided in a stoichiometric excess with respect thereto. Illustratively, the amine or amine moiety is employed in a concentration of 50-150 mM. For utilization at a pH of approximately 7, a concentration of 100 mM is often advantageous. In certain embodiments, the upper limit on amine or amine moiety concentration is determined by the maximum solubility of the amine or moiety in the environment in which it is being used, for example in water. In general, the amount of amine or amine moiety employed is that which is sufficient to effect the
- the assays of the invention are desirably carried out in the presence of an enhancer, typically a compound of the formula
- R is hydrogen or C n H n+1
- R' is C n H 2n
- x is 0 to 70
- n is from 1 to 20.
- n can be from 1 to 4.
- Specific examples are a substance available in commerce under the name Triton X-100, of the formula
- the enhancer is generally utilized in an amount sufficient so that in its presence the desired increase in emission of electromagnetic radiation occurs. Typically, the amount is .01% to 5.0%, more specifically 0.1% to 1.0%, v/v.
- the ECL moiety used in the present invention is induced to emit electromagnetic radiation by stimulating it into an excited state. This is accomplished by exposing the system in which the ECL moiety is incorporated to electrochemical energy.
- the potential at which oxidation of the ECL moiety and the species forming a strong reductant occurs depends upon the exact chemical structures thereof, as well as factors such as the pH of the system and the nature of the electrode used to introduce electrochemical energy. It is well known to those of ordinary skill in the art how to determine the optimal potential and emission wavelength of an electro ⁇ chemiluminescent system. Certain preferred methods of stimulating the ECL system are disclosed in PCT published application US 89/01814, the contents of which are incorporated herein by reference.
- Fig. 8 discloses an advantageous ECL apparatus.
- the method may be employed in other types of ECL apparatus which include a working electrode or other triggering surface to provide electrochemical energy to trigger the ECL moiety into electrochemiluminescence, and the plurality of north-south magnets. While the methods of the invention can be carried out in a static or flow-through mode, apparatus 10 includes a flow-through cell, which provides distinct advantages for many types of samples including binding assay samples. Further details of apparatus for carrying out the ECL assays of the invention are disclosed in published PCT applications US 89/04854 and U.S. 90/01370.
- Apparatus 10 includes an electrochemical cell 12, a light detection/measurement device 14, which may advantageously be a photomultiplier tube (PMT) , photodiode, charge coupled device, photographic film or emulsion or the like, and a pump 16, which is advantageously a peristaltic pump, to provide for fluid transport to, through and from cell 12. Alternatively, a positive displacement pump may be used.
- a shutter mechanism 18 is provided between cell 12 and PMT 14 and is controllably operated to open only so far as to expose PMT 14 to cell 12 during ECL measurement periods. The shutter mechanism may be closed, for example, during maintenance.
- a lightproof housing intended to mount the various components therein and to shield PMT 14 from any external light during the ECL measurements.
- Cell 12 itself includes a first mounting block 20 through which passes an inlet tube 22 and an outlet tube 24, which may be advantageously constructed of stainless steel.
- Mounting block 20 has a first, outer surface 26 and a second, inner surface 28 defining one side of a sample-holding volume 30 of cell 12 in which cell 12 holds the cleaning and/or conditioning and/or measurement solutions during corresponding operations of apparatus 10.
- Inlet and outlet tubes 22, 24 pass through mounting block 20 from outer surface 26 to inner surface 28 and open into sample-holding volume 30.
- a second mounting block 32 advantageously constructed of stainless steel also has a first, outer surface 34 and a second, inner surface 36. Second mounting block 32 is separated from first mounting block 20 by an annular spacer 38, advantageously constructed of Teflon or other non-contaminable material.
- outer surface 34 of mounting block 32 defines part of the second side of the sample-holding volume 30.
- Spacer 38 has an outer portion 40 and a central aperture 42 whose inner edge 44 defines the side wall of sample-holding volume 30.
- Outer portion 40 seals the inner surface 28 of first mounting block 20 to outer surface 34 of second mounting block 32 to prevent any solution from passing out from sample-holding volume 30 between the two surfaces 28, 34.
- Mounting block 32 further has a central aperture 46 in which a window 48 is seal-fitted to define the rest of the second side of sample-holding volume 30 as a continuation of outer surface 34.
- Window 48 is formed of a material which is substantially transparent at the wavelength of electrochemiluminescent light emitted by the ECL moiety. Window 48 is therefore advantageously formed of glass, plastic, quartz or the like.
- Inlet tube 22 intersects sample-holding volume 30 at a first end 50 thereof adjacent to spacer 38 and outlet tube 24 intersects sample-holding volume 30 at a second end 52 thereof, adjacent spacer 38.
- the combination of inlet tube 22, sample-holding volume 30 and outlet tube 24 thereby provides a continuous flow path for the narrow, substantially laminar flow of a solution to, through and from cell 12.
- Arrows A and B represent the flow into and out of inlet tube 22 and outlet tube 24, respectively.
- a working electrode system 54 which, in the illustrated embodiment, includes first and second working electrodes 56 and 58.
- a single working electrode may advantageously be provided, or only electrode 56 may be a working electrode.
- Working elec ⁇ trodes 56, 58 are where the electrochemical and ECL re ⁇ actions of interest can take place.
- Working electrodes 56, 58 are solid voltammetric electrodes and may therefore be advantageously constructed of platinum, gold, carbons or other materials which are effective for this purpose.
- Wire connectors 60, 62 connected to working electrodes 56, 58, respectively, pass out through first mounting block 20.
- a plurality of magnets 27/37 Positioned vertically below the horizontally oriented electrode 56 or electrodes 56, 58 are a plurality of magnets 27/37 in north-south orientation as shown in Figs, l and 2 and which are discussed in more detail below; see also Figs. 3, 5 and 7 and discussion thereof below.
- Connectors 60, 62 are both connected to a first, "working electrode” terminal 64 of a voltage
- Voltage control 66 advantageously operates in the manner of a potentiostat to supply voltage signals to working electrodes 56, 58 and optionally to measure current flowing therefrom during an ECL measurement.
- connectors 60, 62 may be connected to separate terminals of voltage control 66 for individual operation.
- 66 is further effected through a counter electrode 68 and, optionally but advantageously, a reference electrode
- mounting block 32 is made of stainless steel and counter electrode 68 consists in exposed surfaces 72, 74 of mounting block 32.
- Counter electrode 72, 74 and working electrodes 56, 58 provide the interface to impress the potential on the solution within sample-holding volume 30 which energizes the chemical reactions and triggers electrochemiluminescence in the sample and/or provides energy for cleaning and conditioning the surfaces of cell 12.
- Counter electrode 72, 74 is connected by a wire connector 76 to a second,
- Reference electrode 70 provides a reference voltage to which the voltage applied by the working elec ⁇ trodes 56, 58 is referred, for example, +1.2 volts versus the reference.
- Reference electrode 70 is advantageously located in outlet tube 24 at a position 80 spaced from cell 12 and is connected through a wire connector 82 to a third "reference electrode" terminal 84 of voltage control 66. In the three electrode mode, current may not flow through reference electrode 70.
- Reference electrode 70 may be used in a three electrode mode of operation to provide a poised, known and stable voltage and is therefore advantageously constructed of silver/silver chloride (Ag/AgCl) or is a saturated calomel electrode (SCE) .
- Voltage control 66 may be operable in a two electrode mode of operation using only working electrode 56 and electrode 58 as a counter/reference electrode. In this two electrode mode of operation, counter/reference electrode 58 is electrically connected to voltage control terminals 78 and 84 on voltage control 66. In this case, voltage control 66 operates essentially as a battery. Voltage control 66 supplies voltage signals to working and counter electrodes 56 and 58 and optionally measures the current flowing through the respective electrodes.
- Reference electrode 70 may alternatively be a so-called "quasi-reference" electrode constructed of platinum, gold, stainless steel or other material, which provides a less stable voltage, yet one that is measurable with respect to the solution in contact.
- the reference electrode 70 or 58 serves the purpose of providing a reference against which the voltage applied to working electrodes 56 is measured.
- the poised voltage reference is currently considered to be more advantageous.
- Voltage control 66 in its potentiostat operation controls the various electrodes by providing a known voltage at working electrodes 56, 58 with respect to reference electrode 70 while measuring the current flow between working electrodes 56, 58 and counter electrode 72, 74. Potentiostats for this purpose are well known, and the internal structure of voltage control 66 may therefore correspond to any of the conventional, commercially available potentiostats which produce the above-recited functions and so do not form a part of the present invention per se.
- apparatus 10 may alternatively be constructed without an internal voltage control 66, and may be adapted to be connected to an external potentiostat which is separately controlled for providing the required voltage signals to electrodes 56, 58, 72, 74 and 70.
- These voltage signals applied in a specific manner as described below, provide repeatable initial conditions for the surfaces of working electrodes 56, 58 and advantageously for the surfaces of cell 12 as a whole, a feature which contributes significantly to improved precision in ECL measurements.
- Pump 16 is advantageously positioned at outlet tube 24 to "pull" solution from a sample volume in the direction of arrow A into inlet tube 22.
- the solution will flow through inlet tube 22, sample-holding volume 30 and outlet tube 24 past reference electrode 70 and out in the direction of arrow B.
- pump 16 may be positioned at inlet tube 22 to "push” the solution through apparatus 10.
- this same flow path through inlet tube 22, sample-holding volume 30 and outlet tube 24 is used for all solutions and fluids which pass through cell 12, whereby each fluid performs a hydrodynamic cleaning action in forcing the previous fluid out of cell 12.
- Pump 16 may be controlled to suspend its operation to hold a particular solution in cell 12 for any period of time.
- apparatus 10 permits working electrodes to be impressed with a variable voltage or to be continuously held at a preoperative potential while being continuously exposed to one or more solutions without exposing working electrodes 56, 58 (or counter and reference electrodes
- reagent compositions are used.
- the reagent compositions are the components of the assay systems of the invention, i.e., (a) electrolyte, (b) label compound containing an ECL moiety, (c) particles, including magnetically responsive particles,
- SUBSTITUTESHEET (d) analyte of interest or an analog of the analyte of interest, (e) a binding partner of the analyte of interest or of its analog, (f) a reactive component capable of reacting with (d) or (e) , (g) a reductant, or (h) an electrochemiluminescence-reaction enhancer.
- the reagents may be combined with one another for convenience of use, i.e., two component, three component, and higher multiple component mixtures may be prepared, provided that the components are not reactive with one another during storage so as to impair their function in the intended assay. Desirably, the reagents are two- component or multicomponent mixtures which contain particles as well as one or more other components.
- the particles are magnetically responsive or include magnetically responsive particles; and have a density of from 1.0 to 5.0 g/mL and preferably have a density of from 1.1 to 2 g/mL.
- Choice of the optimum density is within the skill of the art, the rate of settling in gravity-driven assays being a trade-off between the speed of the assay and the desire to create a uniform layer of complex on the electrode surface.
- Particles having a wide range of mean diameters can also be employed. Particles having a mean diameter of from 0.001 to 200 ⁇ m such as 0.05 to 200 ⁇ m can be used; and preferably the particles have a mean diameter of from 0.01 to 10 ⁇ m.
- concentration of particles in the assay composition can also be employed.
- concentration can range from 1 to 10,000 ⁇ g/mL to preferably from 5 to 1000 ⁇ g/mL.
- density of the particles, their size and their concentration is selected such that the particles settle at a rate of at least 0.5 mm/min and preferably at a faster rate.
- the art has described a number of magnetic particles which can be used in the assays of the invention. For example, U.S. Patent No. 4,628,037, 4,695,392, 4,695,393, 4,698,302, 4,554,088, U.K.
- the particles may be paramagnetic or ferromagnetic and may be coated with various materials to which binding compounds are coupled so that the magnetic particle can be used in immunoassays.
- the magnetic particles used in the invention have a susceptibility of at least 0.001 cgs units and desirably the susceptibility is at least 0.01 cgs units.
- the magnetic particles may have a broad range of densities, i.e. from substantially less than that of water, 0.01, to 5 g/mL and preferably from 0.5 to 2 g/mL.
- the particle sizes can range from 0.001 to 200, such as 0.001 to 100 or 0.05 to 200 ⁇ m and preferably from 0.01 to 10 ⁇ m.
- the concentration of the particles may range broadly from 1 to 10,000 ⁇ g per mL and preferably is from 5 to 1000 ⁇ g per mL.
- the magnetic particles which are used have a low magnetic resonance, as described for example EP 0,180,384, so that after the magnetic field is removed from the electrode surface, the particles demagnetize and can be swept out of the assay cell.
- the density, concentration and particle size of the magnetic particles is chosen such that the settling time is at least 0.5 mm/min and desirably it is above that rate. In operation of the magnetic cell it is often desirable to remove the magnet means from the electrode surface prior to inducing electrochemiluminescence in order not to interfere with the operation of the photomultiplier tube. Assays
- a flow-through apparatus as generally shown in
- Figs. 1, 2, 3, 5, 7, 8 and 9 employing three electrodes, as described in Figs. 8 and 9, and particularly having the plurality of north-south magnets described in Figs. 1 and 2, is used.
- Inlet Tubing .042" id polypropylene Aspiration Rates:variable from 0.01 to 5 mL/min Potentiostat: microprocessor controlled Luminometer using Hamamatsu R374 PMT (low gain red sensitive tube) ; PMT Voltage variable 0-1400 V (2) Materials
- Dynal M-450 Dynabeads 4.5 ⁇ m diameter superparamagnetic particles, 30 mg/mL, obtained from Dynal, 45 North Station Plaza, Great Neck, NY 11021
- Dynal M-280 Dynabeads 2.8 ⁇ M diameter superparamagnetic particles, 10 mg/mL, obtained for Dynal, 45 North
- the ECL measurement cycle consists of three steps: (l) preconditioning, (2) measuring, and (3) cleaning.
- the preconditioning step involves the application of a voltage triangle wave of 0.0 V to
- the measurement step involves the application of a triangle waveform from +0.6 V to +2.8 V to +2.0 V at 1.0 V/s.
- the cleaning step involves the application of a voltage square wave from +0.0 V to
- EXAMPLE 1 ECL Apparatus and Method for Deposition of Microparticles. Magnetic Collection using a Sedimentation Cell.
- a cell such as a sedimentation cell for conduct of an assay using magnetic force generated by the plurality of north-south magnets of Figs. 1 and 2 to cause the microparticulate to settle is shown in Fig. 3.
- Reference numeral 48 refers to a transparent window, reference numeral 122 to a gasket, reference numeral 22 to the inlet in the cell block, reference numeral 56, 58 to the working electrode, reference numeral 24 to the sample outlet, reference numeral 20 to the cell block itself and reference 27 to the plurality of electromagnets, as shown in Figs. 1 and 2.
- the plane of the cell block is oriented horizontally; the plurality of magnets 27 is vertically below the magnets.
- Labeled microparticles (Dynal) in ECL buffer are drawn to the cell by means of a peristaltic pump. The pump is turned off after the microparticles reach the cell.
- the microparticles in the cell chamber are drawn to the working electrode by means of a magnetic field generated using a plurality of north-south electromagnets as shown in Figs. 1 and 2 and shown generally in Fig. 3 as number 27, which for instance operate at 12 volts and 1.5 amps.
- the electromagnets By application of the electromagnets, the rate of deposition of microparticles is greatly increased over that observed when the microparticles settle solely due to the force of gravity. This is shown in Fig. 4.
- FIG. 5 An assay is carried out in a cell such as a collection cell as described in Fig. 5.
- reference numeral 48 refers to transparent window, reference numeral 132 to a gasket, reference numeral 22 to an inlet in the cell block, reference numeral 56, 58 to a working electrode, reference numeral 20 to the cell block itself, reference numeral 24 to the sample outlet and reference numeral 37 to a plurality of permanent magnets as shown in Figs. 1 and 2.
- the plane of the cell block is oriented horizontally; the plurality of magnets 37 is vertically below the magnets.
- Labeled microparticles (Dynal) in ECL buffer are drawn to the electrochemical cell by
- SHEET means of a peristaltic pump.
- permanent magnets 37 Prior to the sample introduction, permanent magnets 37 are positioned immediately below the working electrode/solution interface at a distance of 0.035 inches. As the sample is being drawn to the cell, the microparticles deposit onto an area over the working electrode, as defined by the area of the magnets. The pump is turned off and the magnetic field withdrawn after the entire sample is deposited. The longer the collection time, the more particles are deposited. Increasing the concentration of particles on the working electrode results in an increased ECL intensity as shown in Fig. 6.
- Microparticles 96 which are attracted to a plurality of magnets 27/37 as shown in Figs. 1 and 2, whether they be permanent magnets or electromagnets, align with the orientation of the magnetic field 98, such as in Fig. 7 which depicts magnetic field 98 and the resultant particle arrangement 96 which is parallel to the surface of the working electrode 56/58, in the vicinity of that surface.
- Figs. 1 and 2 schematically show a cell and magnets 27/37 of Figs. 3, 5, 7, 8 and 9 which is equipped with a magnet system which advantageously imposes field lines which are largely parallel to the plane of the electrode surface 56, 58.
- the magnet system consists of a plurality of individual permanent or electromagnets which are stacked and oriented such that the north and south poles of the magnets 27/37 alternate in the stack.
- the individual magnets of magnets 27/37 are separated by air or any non- magnetically responsive material.
- the arrangement as shown in Figs. 1 and 2 advantageously applies magnetic lines of force to the region above the working electrode which are nearly horizontal to the plane of the electrode. This induces an orientation of the magnetically responsive particles in which the particles lie upon the surface of the electrode and are readily accessible to the electrochemical energy supplied by the electrode; see Fig. 7.
- the magnet system 27/37 shown in Figs. 1 and 2 also is advantageous in that the magnetic field lines do not extend a long distance from the magnet structure; see Fig. 7.
- the magnetic field from such a magnet system is not likely, therefore, to induce permanent magnetic behavior on ferromagnetic materials near the electrode apparatus and will not severely affect the operation of a photomultiplier tube near the flow cell apparatus.
- Uniform and nonuniform, polymeric and non- polymeric, magnetically responsive particles (Dynal, Oslo, Norway; Polysciences, Warrington, PA 18976; Cortex Biochem, San Leandro, CA 94577; Aldrich, Milwaukee, WI 53201) were coated with labeled proteins as described in Example 4.
- the coated particles were washed with ECL buffer three times before making 2 mL of a 300 ⁇ g/mL suspension. Using a peristaltic pump, 500 ⁇ l of the particle suspension is drawn into the flow cell (Example 2) .
- Electrochemiluminescence using the magnetic particles is measured using a Hamamatsu R374 photomultiplier tube centered above the flow cell where particles concentrate on the working electrode surface.
- Table I shows representive ECL photoemission levels obtainable from the labeled-protein coated magnetically responsive particles.
- Ouabain-BSA Conjugate Reagent II was stored at 4°C.
- UB S TITUTE SHEET dissolved in 75 ⁇ L of anhydrous dimethyl sulfoxide (Aldrich). To achieve a 50:1 molar ratio of Ru(bpy) 3 2+ label to protein based on molecular weights of 1057 and 150,000 respectively, 0.176mg Ru(bpy) 3 2+ -NHS (26.4 ⁇ L) was added to the protein solution while shaking. The reaction tube was incubated in the dark at room temperature, 30 minutes, while shaking. The reaction was terminated by the addition of 25 ⁇ L of 1M glycine and incubated for 10 minutes.
- the reaction mixture was purified by passage through a Sephadex G - 25 column (1 X 20 ⁇ m in 0.15M potassium phosphate, 0.15M NaCl with 0.05% sodium azide pH 7.2).
- the Ru(bpy) 3 2+ -labeled mouse anti- TSH fractions were collected and pooled.
- the labeled protein (Reagent V) was determined to have 14 labels per protein.
- Stimulating Hormone (TSH) lOO ⁇ L serum calibrators (London Diagnostics TSH LumiTAG Kit), 25 ⁇ L Ru(bpy) 3 2+ -labeled mouse anti-TSH (Reagent V) in ECL buffer and 25 ⁇ L Sheep anti-TSH-DYNAL particles (Reagent I) in ECL buffer were combined and incubated in polypropylene tubes for 15 minutes, at room temperature, with mixing. Prior to reading results, ImL of ECL buffer was added. The electrochemiluminescence (ECL) for each sample is read as described in Example 2. The ECL counts are directly proportional to the concentration of analyte present in the sample (increasing counts as the concentration of analyte increases) . Table III demonstrates a representative assay curve.
- EXAMPLE 16 Preparation of Nucleic Acid Magnetic Particles And ECL Use Dynal M 450 particles were activated with 2- fluoro-1-methylpyridinium toluene-4-sulfonate using standard procedures (6) . These activated particles were then reacted with oligonucleotides JK8 and JK8C.
- ECL after hybridization to particles is demonstrated by the hybridization of particles coupled to JK8 and JK8C with Ru(bpy) 3 2+ -label oligonucleotide JK7; JK7 is complementary to the JK8 sequence and not complementary to the JK8C sequence.
- Individual lots of particles (300 ⁇ g) in ECL buffer are mixed with 50 ⁇ l of ECL buffer containing 12.5, 6.3, 3.01 and 1.5 fmoles of label JK7. These mixtures are hybridized for 4 hours at 52°C followed by washing with ImL ECL buffer and then resuspension on 830 ⁇ l of ECL buffer. The samples are analyzed as described in Example 2.
- the JK8 particles display over 1000 times more ECL counts than the HK8C particles; at 6.3 fmoles the JK8 particles display nearly 1000 times more ECL counts than the JK8C particles; and, at 3.02 and 1.5 fmoles, the JK8 particles display about 5 and about 3 times more ECL counts than the JK8C particles respectively. This demonstrates the ability to detect by specific hybridization the presence of specific sequences directly immobilized on the surface of particles by ECL.
- Dynal M 450 particles were activated with 2- fluoro-1-methylpyridinium toluene-4-sulfonate using standard procedures (6) . The activated particles were then reacted with streptavidin (Sigma Ltd) . Activated particles (50mg) were washed with 0.1M NaHC0 3 followed by the addition of streptavidin (1.5mg) and reacted overnight. The particles were blocked by the addition of ethanolamine (4mL, 0.1M).
- the coupled particles were mixed with 0.5mg/mL single stranded salmon sperm DNA in ECL buffer, washed 4-5 times into ECL buffer and resuspended at lOmg/mL in ECL buffer containing lOO ⁇ g/mL single stranded salmon sperm DNA.
- the streptavidin particles from Dynal M-280 also proved valuable but gives lower signals with the current assay sequence.
- particles were blocked with BSA after antigen or antibody coupling using the buffers used for passive coating.
- the particles were finally resuspended in 29.7 mL of ECL diluent and 300 ⁇ l tRNA (lOmg/mL) to a final concentration of 10 mg/mL particles + 100 ⁇ g/mL tRNA.
- the assay format described here makes use of two oligonucleotides, both of which hybridize to the same DNA strand next to each other, one probe allows capture; the other labels the complex (sandwich hybridization) .
- This assay was demonstrated using E.coli DNA and probes specific for the trp E/D gene region.
- the E.coli DNA was prepared following standard protocols (1) .
- the salmon sperm control DNA was purchased from Sigma Ltd.
- To the samples of DNA were added 14 ⁇ l of hybridization buffer (10X PBS, lOmMEDTA and 0.7%SDS), 2ng of biotin labeled TRP.C04 and 5ng of Ru(bpy) 3 2+ -label TRP.C03. These samples were made up to lOO ⁇ l with water.
- the samples were heated to 97°C and incubated at 97°C for lOmin, cooled to 50°C and hybridized for 2hrs.
- To these samples we added 20 ⁇ l of streptavidin coated magnetic particles II and mixed for 2hrs at room temperature. The particles were then washed 4 times in ECL buffer resuspended in 500 ⁇ l of ECL buffer and are analyzed as described in Example 2.
- the positive DNA is E.coli and the negative DNA is salmon sperm. The results obtainable are shown in Table VII.
- streptavidin coated magnetic particles I can be similarly used in the fashion that the streptavidin coated magnetic particles II are used in this example.
Abstract
Disclosed and claimed are methods and apparatus for performing a binding assay for an analyte of interest present in a sample based upon measurement of electrochemiluminescence at an electrode. The method uses magnetically responsive particles. The method and apparatus call for a plurality of electromagnets or permanent magnets in north-south orientation for imposing a magnetic field so as to collect the particles.
Description
Method and Apparatus for Magnetic Microparticulate Based Luminescence Assay Including Plurality of Magnets
Field of The Invention This invention relates to a method for performing a binding assay for an analyte of interest present in a sample based upon measurement of electroche iluminescence at an electrode wherein a complex including the sample, an assay-performance substance containing a component linked to a label capable of being induced to electrochemiluminesce, and a plurality of magnetically responsive suspended particles capable of binding with the analyte or substance is formed; the complex is collected at the surface of an electrode by the imposition of a magnetic field on the particles by a plurality of permanent magnets or electromagnets in north-south orientation; the label is induced to luminesce; and, the luminescence emitted is measured. The invention also relates to apparatus for performing such a method having the plurality of permanent magnets or electromagnets in north-south orientation.
Background of The Invention Numerous methods and systems have been developed for the detection and quantitation of analytes of interest in biochemical and biological substances. Methods and systems which are capable of measuring trace amounts of microorganisms, pharmaceuticals, hormones, viruses, antibodies, nucleic acids and other proteins are of great value to researchers and clinicians. A very substantial body of art has been developed based upon the well known binding reactions, e.g., antigen-antibody reactions, nucleic acid hybridization techniques, and protein-ligand systems. The high degree of specificity in many biochemical and biological binding systems has led to many assay methods and systems of value in research and diagnostics. Typically, the existence of an analyte of interest is
"
indicated by the presence or absence of an observable "label" attached to one or more of the binding materials. Of particular interest are labels which can be made to luminesce through photochemical, chemical, and electrochemical means. "Photoluminescence" is the process whereby a material is induced to luminesce when it absorbs electromagnetic radiation. Fluorescence and phosphorescence are types of photoluminescence. "Chemiluminescent" processes entail the creation of luminescent species by chemical transfer of energy. "Electrochemiluminescence" entails creation of luminescent species electrochemically.
Chemiluminescent assay techniques where a sample containing an analyte of interest is mixed with a reactant labeled with a chemiluminescent label have been developed. The reactive mixture is incubated and some portion of the labeled reactant binds to the analyte. After incubation, the bound and unbound fractions of the mixture are separated and the concentration of the label in either or both fractions can be determined by chemiluminescent techniques. The level of chemiluminescence determined in one or both fractions indicates the amount of analyte of interest in the biological sample. Electrochemiluminescent (ECL) assay techniques are an improvement on chemiluminescent techniques. They provide a sensitive and precise measurement of the presence and concentration of an analyte of interest. In such techniques, the incubated sample is exposed to a voltammetric working electrode in order to trigger luminescence. In the proper chemical environment, such electrochemiluminescence is triggered by a voltage impressed on the working electrode at a particular time and in a particular manner. The light produced by the label is measured and indicates the presence or quantity of the analyte. For a fuller description of such ECL techniques, reference is made to PCT published
application US85/01253 (W086/02734) , PCT published application number US87/00987, and PCT published application U.S. 88/03947. The disclosures of the aforesaid applications are incorporated by reference. It is desirable to carry out electrochemiluminescent assays without the need for a separation step during the assay procedure and to maximize the signal modulation at different concentrations of analyte so that precise and sensitive measurements can be made. Among prior art methods for nonseparation assays are those which employ microparticulate matter suspended in the assay sample to bind one or more of the binding components of the assay.
U.S. Patent No. 4,305,925 relates to the detection and determination of clinically relevant proteins and peptides by means of nephelometric and tur- bidi etric methods. The methods disclosed involve binding the antigen or antibody to latex particles which perform the function of light scattering or adsorption. U.S. Patent No. 4,480,042 relates to techniques employing particle reagents consisting of shell-core particles. The shell contains functional groups to which compounds of biological interest can be covalently bonded, and the high refractive index of the core results in high sensitivity to light scattering measurements. The technique is based upon agglutination reactions which result from the reaction of bivalent antibodies with multivalent antigens of interest to produce aggregates which can be detected and/or measured in various ways. U.S. Patent No. 4,419,453 likewise relates to the use of colored latex agglutination test methods useful for detecting the presence of immunochemicals such as antibodies and immunogens.
Based upon this prior art, it would not have appeared possible to use microparticulate matter in assays wherein a luminescent phenomenon is measured. One would expect that the luminescence from free
chemiluminescent or electrochemiluminescent moieties would be absorbed, scattered, or otherwise suffer interference from the microparticulate matter.
Contrary to that expectation, U.S. Application Serial No. 539,389 (PCT published application U.S. 89/04919) teaches sensitive, specific binding assay methods based on a luminescent phenomenon wherein inert microparticulate matter is specifically bound to one of the binding reactants of the assay system. The assays may be performed in a heterogeneous (one or more separation steps) assay format and may be used most advantageously in a homogeneous (nonseparation) assay format.
U.S. 89/04919 relates to a composition for an assay based upon a binding reaction for the measurement of luminescent phenomenon, which composition includes a plurality of suspended particles having a surface capable of binding to a component of the assay mixture. In another aspect, it is directed to a system for detecting or quantitating an analyte of interest in a sample, which system is capable of conducting the assay methods using the assay compositions of the inventions. The system includes means for inducing the label compound in the assay medium to luminesce, and means for measuring the luminescence to detect the presence of the analyte of interest in the sample.
It was found that the binding of that component of the assay system to which an electrochemiluminescent moiety has been linked, to suspended microparticulate matter, greatly modulates the intensity of the luminescent signal generated by the electrochemiluminescent moiety linked to that component, thereby providing a means of monitoring the specific binding reaction of the assay system. Even more sur- prisingly, the suspended particles were found to have little or no effect on the intensity of the luminescent signal generated by the electrochemiluminescent moiety
linked to the component of the system which remains un¬ bound to the suspended microparticulate matter.
Thus, U.S. 89/04919 is directed to methods for the detection of an analyte of interest in a sample, which method includes the steps of (1) forming a composition comprising (a) a sample suspected of containing an analyte of interest, (b) an assay- performance-substance selected from the group consisting of (i) analyte of interest or analog of the analyte of interest, (ii) a binding partner of the analyte of interest or its said analog, and (iii) a reactive component capable of binding with (i) or (ii) , wherein one of said substances is linked to a label compound having a chemical moiety capable of being induced to luminesce, and (c) a plurality of suspended particles capable of specifically binding with the analyte and/or a substance defined in (b) (i) , (ii) , or (iii) ; (2) incubating the composition to form a complex which includes a particle and said label compound; (3) inducing the label compound to luminesce; and (4) measuring the luminescence emitted by the composition to detect the presence of the analyte of interest in the sample. Those same methods may be used to quantify the amount of analyte in a sample by comparing the luminescence of the assay composition to the luminescence of a composition containing a known amount of analyte.
Analogs of the analyte of interest, which may be natural or synthetic, are compounds which have binding properties comparable to the analyte, but include compounds of higher or lower binding capability as well. Binding partners suitable for use in the present invention are well-known. Examples are antibodies, enzymes, nucleic acids, lectins, cofactors and receptors. The reactive components capable of binding with the analyte or its analog and/or with a binding partner thereof may be a second antibody or a protein such as Protein A or Protein G or may be avidin or biotin or
SUBSTITUTE SHEET
another component known in the art to enter into binding reactions.
Advantageously, the luminescence arises from electrochemiluminescence (ECL) induced by exposing the label compound, whether bound or unbound to specific binding partners, to a voltammetric working electrode. The ECL reactive mixture is controllably triggered to emit light by a voltage impressed on the working electrode at a particular time and in a particular manner to generate light. Although the emission of visible light is an advantageous feature the composition or system may emit other types of electromagnetic radiation, such as infrared or ultraviolet light, X-rays, microwaves, etc. Use of the terms "electrochemiluminescence," "electrochemiluminescent," "luminescence," "luminescent," and "luminesce" includes the emission of light and other forms of electromagnetic radiation.
The methods taught in U.S. 89/04919 permit the detection and quantitation of extremely small quantities of analytes in a variety of assays performed in research and clinical settings. The demands of researchers and clinicians makes it imperative, however, to lower the detection limits of assays performed by these methods to increase the sensitivities of those assays and to increase the speed at which they can be performed.
Various methods are known in the art for increasing the signal from labeled species by concentrating them before subjecting them to a measurement step. In U.S. Patent No. 4,652,333, for example, particles labeled with fluorescent, phosphorescent or atomic fluorescent labels are concentrated by microfiltration before a measurement step is performed. It is also known in the art to concentrate labeled immunochemical species prior to a measurement step, by, e.g., drawing magnetically responsive labeled
particles to the surface of a measurement vessel. In U.S. Patents No. 4,731,337, 4,777,145, and 4,115,535, for example, such particles are drawn to the vessel wall and then are irradiated to excite a fluorophoric emission of light.
In U.S. Patent No. 4,945,045, particles are concentrated on a magnetic electrode. An electrochemical reaction takes place at the electrode facilitated by a labeled chemical mediator. The immunochemical binding reaction alters the efficiency of the mediator resulting in a modulated signal when binding takes place.
These prior art methods are not relevant to the surface selective excitation processes of the invention. While not being bound by any particular mechanistic explanation of surface excitation, e.g., electrochemiluminescence, it is believed that the label on the solid-phase complex must be oxidized at the electrode. This requires that an electron move from the label to the electrode. It is believed that the electron makes this "jump" by a phenomenon known as tunneling in which the electron passes through space (a region where its potential energy is very high, e.g., the solution) without having to go "over" the potential energy barrier. It can tunnel through the energy barrier, and thus, move from one molecule to another or from one molecule to an electrode without additional energy input. However, this tunneling phenomenon can only operate for very short distances. The probability of the tunneling phenomenon falls off exponentially as the distance between the two species increases. The probability of the tunneling phenomenon occurring between two species is fairly high if the distance is less than 25 Angstroms (2.5 nm) but is fairly low if the distance is greater. The distance of 25 A is a rule-of-thumb used by those skilled in the art but is not an absolute limitation.
Accordingly, only those ECL labels with 25 A of the surface of the electrode can be expected to
participate in the ECL process. The area of the particle which is within 25 A of the surface of an electrode is typically extremely small.
Accordingly, one would not expect that ECL from a particle surface would be measurable to any significant degree. Moreover, the light which is produced by the ECL process must pass through the particle to get to the photomultiplier. Since the particles are essentially opaque (a concentrated suspension of them is black) one would not expect that, even if significant amounts of light could be produced by ECL, that the light could pass through the particle and be measured by the photomultiplier. Moreover, the art does not teach or suggest the plurality of north-south magnets which is particular to the method and apparatus of this invention.
Objects of The Invention It is an object of this invention to provide separation (heterogeneous) or non-separation (homogeneous) , specific bonding methods and apparatus, based upon the measurement of electrochemiluminescence emitted from an assay composition containing magnetic microparticulate matter and employing a plurality of north-south oriented magnets.
It is a further and related object to provide such methods and apparatus having improved sensitivity, faster assay time, greater specificity, lower detection limits and greater precision than has heretofore been achieved.
Description of the Invention Definition of Terms
The term "ECL moiety," "metal-containing ECL moiety" "label," "label compound," and "label substance," are used interchangeably. It is within the scope of the invention for the species termed "ECL moiety," "metal- containing ECL moiety," "organo-metallic," "metal chelate," "transition metal chelate" "rare earth metal chelate," "label compound," "label substance" and "label"
to be linked to molecules such as an analyte or an analog thereof, a binding partner of the analyte or an analog thereof, and further binding partners of such aforementioned binding partner, or a reactive component capable of binding with the analyte, an analog thereof or a binding partner as mentioned above. The above- mentioned species can also be linked to a combination of one or more binding partners and/or one or more reactive components. Additionally, the aforementioned species can also be linked to an analyte or its analog bound to a binding partner, a reactive component, or a combination of one or more binding partners and/or one or more reactive components. It is also within the scope of the invention for a plurality of the aforementioned species to be bound directly, or through other molecules as discussed above, to an analyte or its analog. For purposes of brevity, these ligands are referred to as an assay-performance-substance.
The terms detection and quantitation are referred to as "measurement", it being understood that quantitation may require preparation of reference compositions and calibrations.
The terms collection and concentration of complex may be used interchangeably to describe the concentration of complex within the assay composition and the collection of complex at, e.g., an electrode surface.
Brief Description of the Drawings
Figs. 1 and 2 show the cell and plurality of magnets for performing the magnetic microparticulate- based separation or non-separation assay method of the invention; the plurality of magnets of the magnet system imposes field lines which are largely parallel to the plane of the electrode surface.
Fig. 3 is a schematic representation of a sedimentation assay cell which employs electromagnets of Figs. 1 and 2 to cause the complex to settle on the electrode surface.
Fig. 4 is a graph showing the relative rates of settling of microparticulate complex under the influence of a magnetic field (Figs. 1 and 2) and of gravity, respectively, i.e., a comparison of microparticulate settling times between a magnetic field (Figs. 1, 2) induced settling and gravity settling wherein values for the magnetic field settling are represented by open circles and the values for gravity settling are represented by darkened circles. Fig. 5 is a schematic representation of a collection cell including a permanent magnets of Figs. 1 and 2.
Fig. 6 is a graph showing the increase in ECL intensity as a function of time in assays conducted with the cell of Fig. 5, i.e., the effect of collection time on ECL intensity.
Fig. 7 is a schematic representation of the lines of force in the vicinity of the electrode surface of the magnets (Figs. 1 and 2) beneath the electrode surface.
Fig. 8 is a schematic drawing of a cell for performing the microparticulate-based nonseparation and separation assays of the invention; the cell employs a working electrode and plurality of magnets as in Figs. 1 and 2.
Fig. 9 is a simplified diagram of a voltage control apparatus for use with the cell of Fig. 8.
Brief Description of the Invention In its broadest embodiment, the invention is in a method for performing a binding assay for an analyte of interest present in a sample. The steps include: (a) forming a composition containing (i) said sample (ii) an assay-performance-substance which contains a component linked to a label compound capable of being
SHE T
induced to electrochemiluminesce, and (iii) a plurality of magnetically responsive suspended particles capable of specific binding with the analyte and or said assay- performance-substance; (b) incubating said composition to form a complex which includes a particle and said label compound; (c) introducing said composition into an assay cell;
(d) collecting said complex at the surface of an electrode by imposition of a magnetic field on said particles; (e) inducing the label compound in said collected complex to luminescence by imposing a voltage on said electrode; and
(f) measuring the emitted luminescence at the electrode surface to measure the presence of the analyte of interest in the sample; wherein a plurality of magnets, permanent magnets or electromagnets, in north- south orientation are positioned vertically below a horizontally oriented electrode surface.
The invention also provides an apparatus for performing a binding assay for an analyte of interest present in a sample based upon measurement of electrochemiluminescence at an electrode surface comprising:
(a) a cell defining an assay sample containing volume and having inlet and outlet means, an electrode, and further including means for obtaining a substantially even distribution of said complex on said electrode surface;
(b) means to impress a voltage upon said electrode; and
(c) m e a n s t o m e a s u r e t h e electrochemiluminescence generated at said electrode; the
SUBSTITUTE SHEET
means for obtaining an even distribution of complex includes means for generating a magnetic field oriented with respect to said electrode so that the lines of force of said magnetic field are substantially parallel with the surface of said electrode in the region of said surface; and the means for generating a magnetic field includes a plurality of magnets in north-south orientation and separated by non-magnetic material positioned vertically below said electrode. Several different heterogeneous and homogeneous formats for binding assays can be implemented using the method described above to collect and concentrate the complex on the surface of an electrode. In a heterogeneous binding assay the complex is separated from the composition before measuring luminescence from the label. In homogeneous assays, no separation of the bound (to the solid phase) and unbound labeled reagents is made.
In a heterogeneous assay, when the complex is concentrated on the surface of the working electrode, the measured signal from the label is much greater than it would be in the absence of a collection step. The signal from the uncomplexed labeled reagents, in contrast, is not changed. Hence, despite the presence of the uncomplexed labeled reagents in the measurement cell, the signal from the collected complex is stronger than in an assay without collection of complex. The detection limit for the binding assay is, much improved as a result of the collection procedure. In the invention, an in-situ separation step can be included in the homogeneous binding assay procedure. After the assay composition, i.e., sample, assay performance substance and particles have been pumped into the measurement cell and the complex captured upon the working electrode, a second fluid is pumped through the cell which is free of label or labeled reagents, thereby performing an in-situ wash or
SUBSTITUTE SHEET
separation of the complex from unbound components of the assay composition. This assay procedure is technically a heterogeneous binding assay. However, the ability to perform the separation inside the measurement cell is advantageous in that it does not require additional separation apparatus and the procedure is generally much faster than external separation methods.
Heterogeneous binding assays are conducted using the invention by mixing the components of the assay composition and allowing them to react for a predetermined length of time. The assay composition is then subjected to a separation step wherein the solution is separated from the particles . Electrochemiluminescence is then measured from either the complex or the solution. Measuring the ECL from the complex after a concentration step permits measurement of analyte with better accuracy and with a lower detection limit than is possible without concentration.
Detailed Description of the Invention
The invention, as well as other objects and features thereof, will be understood more clearly and fully from the following description of certain preferred embodiments. The invention is broadly applicable to analytes of interest which are capable of entering into binding reactions. These reactions include, e.g., antigen- antibody, ligand receptor, DNA and RNA interactions, and other known reactions. The invention relates to a method and apparatus for qualitatively and quantitatively detecting the presence of such analytes of interest in a multicomponent sample; the method and apparatus involve a plurality of north-south magnets. The Samples The sample which may contain the analyte of interest, which may be in solid, emulsion, suspension, liquid, or gas form, may be derived from, for example.
cells and cell-derived products, water, food, blood, serum, hair, sweat, urine, feces, tissue, saliva, oils, organic solvents or air. The sample may further comprise, for example, water, acetonitrile, dimethyl sulfoxide, dimethyl formamide, n-methyl-pyrrolidone or alcohols or mixtures thereof. The Analytes
Typical analytes of interest are a whole cell or surface antigen, subcellular particle, virus, prion, viroid, antibody, antigen, hapten, fatty acid, nucleic acid, protein, lipoprotein, polysaccharide, lipopolysaccharide, glycoprotein, peptide, polypeptide, cellular metabolite, hormone, pharmacological agent, synthetic organic molecule, organometallic molecule, tranquilizer, barbiturate, alkaloid, steroid, vitamin, amino acid, sugar, lectin, recombinant or derived protein, biotin, avidin, streptavidin, or inorganic molecule present in the sample. Typically, the analyte of interest is present at a concentration of 10~3 molar or less, for example, as low as 10~12 molar or lower. Assav-Performance-Substance
The assay-performance-substance which is combined with the sample containing the analyte of interest contains at least one substance selected from the group consisting of (i) added analyte of interest or its analog, as defined above, (ii) a binding partner of the analyte of interest or its said analog, and (iii) a reactive component, as defined above, capable of binding with (i) or (ii) , wherein one of said substances is linked to a compound or moiety, e.g. an ECL moiety capable of being induced to luminesce. The labeled substance may be a whole cell or surface antigen, a subcellular particle, virus, prion, viroid, antibody, antigen, hapten, lipid, fatty acid, nucleic acid, polysaccharide, protein, lipoprotein, lipopolysaccharide, glycoprotein, peptide, polypeptide, cellular metabolite, hormone, pharmacological agent, tranquilizer,
barbiturate, alkaloid, steroid, vitamin, amino acid, sugar, nonbiological polymer (preferably soluble) , lectin, recombinant or derived protein, synthetic organic molecule, organometallic molecule, inorganic molecule, biotin, avidin or streptavidin. In one embodiment, the reagent is an electrochemiluminescent moiety conjugated to an antibody, antigen, nucleic acid, hapten, small nucleotide sequence, oligomer, ligand, enzyme, or biotin, avidin, streptavidin. Protein A, Protein G, or complexes thereof, or other secondary binding partner capable of binding to a primary binding partner through protein interactions.
Analogs of the analyte of interest, which can be natural or synthetic, are typically compounds which have binding properties comparable to the analyte, but can also be compounds of higher or lower binding capability. The reactive component capable of binding with the analyte or its analog, and/or with a binding partner thereof, and through which the ECL moiety can be linked to the analyte, is suitably a second antibody or a protein such as Protein A or Protein G, or avidin or biotin or another component known in the art to enter into binding reactions. The Labels Advantageously, the ECL moieties are metal chelates. The metal of that chelate is suitably any metal such that the metal chelate will luminesce under the electrochemical conditions which are imposed on the reaction system in question. The metal of such metal chelates is, for instance, a transition metal (such as a d-block transition metal) or a rare earth metal. The metal is preferably ruthenium, osmium, rhenium, iridium, rhodium, platinum, indium, palladium, molybdenum, tech- netium, copper, chromium or tungsten. Especially preferred are ruthenium and osmium.
The ligands which are linked to the metal in such chelates are usually heterocyclic or organic in
SUBSTITUTE SHEET
nature, and play a role in determining whether or not the metal chelate is soluble in an aqueous environment or in an organic or other nonaqueous environment. The ligands can be polydentate, and can be substituted. Polydentate ligands include aromatic and aliphatic ligands. Suitable aromatic polydentate ligands include aromatic heterocyclic ligands. Preferred aromatic heterocyclic ligands are nitrogen-containing, such as, for example, bipyridyl, bipyrazyl, terpyridyl, and phenanthrolyl. Suitable substituents include for example, alkyl, substituted alkyl, aryl, substituted aryl, aralkyl, substituted aralkyl, carboxylate, carboxaldehyde, carboxamide, cyano, amino, hydroxy, imino, hydroxycarbonyl, aminocarbonyl, amidine, guanidinium, ureide, sulfur-containing groups, phosphorus containing groups, and the carboxylate ester of N-hydroxy- succinimide. The chelate may have one or more monodentate ligands, a wide variety of which are known to the art. Suitable monodentate ligands include, for example, carbon monoxide, cyanides, isocyanides, halides, and aliphatic, aromatic and heterocyclic phosphines, amines, stilbenes, and arsines.
Examples of suitable chelates are bis [(4,4'- carbomethoxy)-2,2'-bipyridine] 2-[3-(4-methyl-2,2'-bi- pyridine-4-yl)propyl]-l,3-dioxolane ruthenium (II); bis (2,2'bipyridine) [4-(butan-1-al)-4'-methyl-2,2'-bi¬ pyridine] ruthenium (II) ; bis (2,2'-bipyridine) [4-(4'- methyl-2,2'-bipyridine-4'-yl)-butyric acid] ruthenium (II); tris (2,2'bipyridine) ruthenium (II); (2,2'- bipyridine) [bis-bis(l,2-diphenylphosphino)ethylene] 2- [3-(4-methyl-2,2'-bipyridine-4'-yl) ropyl]-1,3-dioxolane osmium (II); bis (2,2'-bipyridine) [4-(4'-methyl-2,2'- bipyridine)-butylamine] ruthenium (II); bis (2,2'- bipyridine) [l-bromo-4(4'-methyl-2,2'-bipyridine-4- yl)butane] ruthenium (II) ; bis (2,2'- bipyridine)maleimidohexanoic acid, 4-methyl-2,2'- bipyridine-4'-butylamide ruthenium (II) . Other ECL
moieties are described in PCT published application US87/00987 and PCT published application 88/0394, incorporated herein by reference.
The function of the ECL moieties is to emit electromagnetic radiation as a result of introduction into the reaction system of electrochemical energy. In order to do this, they must be capable of being stimulated to an excited energy state and also capable of emitting electromagnetic radiation, such as a photon of light, upon descending from that excited state. While not wishing to be bound by theoretical analysis of the mechanism of the ECL moiety's participation in the elec¬ trochemiluminescent reaction, we believe that it is oxidized by the introduction of electrochemical energy into the reaction system and then, through interaction with a reductant present in the system, is converted to the excited state. This state is relatively unstable, and the metal chelate quickly descends to a more stable state. In so doing, the chelate gives off electromagnetic radiation, such as a photon of light, which is detectable.
The amount of metal chelate or other metal- containing ECL moiety incorporated in accordance with the invention will vary from system to system. Generally, the amount of such moiety utilized is that amount which is effective to result in the emission of a detectable, and if desired, quantitatable , emission of electromagnetic energy, from the aforementioned composition or system. The detection and/or quantitation of an analyte of interest is typically made from a comparison of the luminescence from a sample containing an analyte of interest and an ECL moiety to the luminescence emitted by a calibration standard developed with known amounts of the analyte of interest and ECL moiety. This assumes a homogeneous format. In the heterogeneous mode, a separation as discussed previously is carried out prior to ECL analysis.
TITUTE SHEET
As can be appreciated by one of ordinary skill in the art, the identity and amount of the metal- containing ECL moiety will vary from one system to another, depending upon prevailing conditions. The appropriate metal-containing ECL moiety, and sufficient amount thereof to obtain the desired result, can be determined empirically by those of ordinary skill in the art, once equipped with the teachings herein, without undue experimentation. The Particles
The particles advantageously comprise micro¬ particulate matter having a diameter of 0.001 to 200 μm, such as 0.05 μm to 200 μm, preferably 0.1 μm to 100 μm, most preferably 0.5 μm to 10 μm, and a surface component capable of binding to the analyte and/or one or more of the other substances defined above. For example, the microparticulate matter may be crosslinked starch, dextrans, cellulose, proteins, organic polymers, styrene copolymer such as styrene/butadiene copolymer, acrylonitrile/butadiene/styrene copolymer, vinylacetyl acrylate copolymer, or vinyl chloride/aerylate copolymer, inert inorganic particles, chromium dioxide, oxides of iron, silica, silica mixtures, and proteinaceous matter, or mixtures thereof. Desirably, the particles are suspended in the ECL system. However, the particles must be or must include magnetically responsive particles. It is also noted that samples, analytes, assay-performance- substances, labels, assay media, reagents and other assay components, and particles, including any of the aforementioned in combination, as well as any components of the aforementioned, are not per se contemplated as within the scope of the invention. Assay Media
In order to operate a system in which an electrode introduces electrochemical energy, it is necessary to provide an electrolyte in which the electrode is immersed and which contains the ECL moiety.
The electrolyte is a phase through which charge is carried by ions. Generally, the electrolyte is in the liquid phase, and is a solution of one or more salts or other species in water, an organic liquid or mixture of organic liquids, or a mixture of water and one or more organic liquids. However, other forms of electrolyte are also useful in certain embodiments of the invention. For example, the electrolyte may be a dispersion of one or more substances in a fluid —e.g., a liquid, a vapor, or a supercritical fluid —or may be a solution of one or more substances in a solid, a vapor or supercritical fluid.
The electrolyte is suitably a solution of a salt in water. The salt can be a sodium salt or a potassium salt preferably, but incorporation of other cations is also suitable in certain embodiments, as long as the cation does not interfere with the electrochemiluminescent interaction sequence. The salt's anion may be a phosphate, for example, but the use of other anions is also permissible in certain embodiments of the invention —once again, as long as the selected anion does not interfere with the electrochemiluminescent interaction sequence.
The composition may also be nonaqueous. While supercritical fluids can in certain instances be employed advantageously, it is more typical to utilize an electro¬ lyte comprising an organic liquid in a nonaqueous composition. Like an aqueous electrolyte, the nonaqueous electrolyte is also a phase through which charge is carried by ions. Normally, this means that a salt is dissolved in the organic liquid medium. Examples of suitable organic liquids are acetonitrile, dimethylsulfoxide (DMSO) , dimethylformamide (DMF) , methanol, ethanol, and mixtures of two or more of the foregoing. Illustratively, tetraalkylammonium salts, such as tetrabutyla monium tetrafluoroborate, which are soluble in organic liquids can be used with them to form
nonaqueous electrolytes.
The electrolyte is, in certain embodiments of the invention, a buffered system. Phosphate buffers are often advantageous. Examples are an aqueous solution of sodium phosphate/sodium chloride, and an aqueous solution of sodium phosphate/sodium fluoride. Other Assay Components
As described PCT published application U.S. 89/04859, entitled Electrochemiluminescent Reaction Utilizing Amine-Derived Reductant, the disclosure of which is incorporated by reference, it is desirable to include a reductant, typically an amine or a ine moiety (of a larger molecule) which can be oxidized and spontaneously decomposed to convert it into a highly reducing species. It is believed that the amine or amine moiety is also oxidized by electrochemical energy introduced into the reaction system. The amine or amine moiety loses one electron, and then deprotonates, or rearranges itself, into a strong reducing agent. This agent interacts with the oxidized metal-containing ECL moiety and causes it to assume the excited state discussed above. In order to carry out its role, the amine or amine moiety preferably has a carbon-centered radical with an electron which can be donated from such carbon, and an alpha carbon which can then act as a proton donor during deprotonation in order to form the reductant. The amine-derived reductant provides the necessary stimulus for converting the metal-containing ECL moiety to its excited state, from which detectable electromagnetic radiation is emitted.
A wide range of amines and corresponding amine moieties can be utilized in practicing the present inven¬ tion. Generally, the amine or amine moiety is chosen to suit the pH of the system which is to be electrochemiluminescently analyzed. Another relevant factor is that the amine or amine moiety should be compatible with the environment in which it must function
during analysis, i.e., compatible with an aqueous or nonaqueous environment, as the case may be. Yet another consideration is that the amine or amine moiety selected should form an amine-derived reductant under prevailing conditions which is strong enough to reduce the oxidized metal-containing ECL moiety in the system.
Amines (and corresponding moieties derived therefrom) which are advantageously utilized in the present invention are aliphatic amines, such as primary, secondary and tertiary alkyl amines, the alkyl groups of each having from one to three carbon atoms, as well as substituted aliphatic amines. Tripropyl amine is an especially preferred amine as it leads to, comparatively speaking, a particularly high-intensity emission of electromagnetic radiation, which enhances the sensitivity and accuracy of detection and quantitation with embodiments in which it is used. Also suitable are diamines, such as hydrazine, and polymines, such as poly(ethyleneimine) . Examples of other amines suitable for practicing the invention are triethanol amine, triethyl amine, l,4-diazabicyclo-(2.2.2)-octane, 1- piperidine ethanol, l,4-piperazine-bis-(ethane-sulfonic acid), tri-isopropyl amine and poly(ethyleneimine) .
Typically, the metal-containing ECL moiety utilized in the present invention is the reaction- limiting constituent. Accordingly, it is also typical that the amine or amine moiety is provided in a stoichiometric excess with respect thereto. Illustratively, the amine or amine moiety is employed in a concentration of 50-150 mM. For utilization at a pH of approximately 7, a concentration of 100 mM is often advantageous. In certain embodiments, the upper limit on amine or amine moiety concentration is determined by the maximum solubility of the amine or moiety in the environment in which it is being used, for example in water. In general, the amount of amine or amine moiety employed is that which is sufficient to effect the
TUTE SHEET
transformation of the oxidized metal-containing ECL moiety into its excited state so that luminescence occurs. Those of ordinary skill in the art, equipped with the teachings herein, can determine empirically the amount of amine or amine moiety advantageously used for the particular system being analyzed, without undue experimentation.
As described in PCT published application US 89/04915, entitled Enhanced Electrochemiluminescent Reaction, the contents of which are incorporated by reference, the assays of the invention are desirably carried out in the presence of an enhancer, typically a compound of the formula
wherein R is hydrogen or CnHn+1, R' is CnH2n, x is 0 to 70, and n is from 1 to 20. Preferably, n can be from 1 to 4. Specific examples are a substance available in commerce under the name Triton X-100, of the formula
CH- CH-
CH, CH,
wherein x is 9-10, and a substance available in commerce under the name Triton N-401 (NPE-40) , of the formula
wherein x is 40. The enhancer is generally utilized in an amount sufficient so that in its presence the desired increase in emission of electromagnetic radiation occurs. Typically, the amount is .01% to 5.0%, more specifically 0.1% to 1.0%, v/v.
The ECL moiety used in the present invention is
induced to emit electromagnetic radiation by stimulating it into an excited state. This is accomplished by exposing the system in which the ECL moiety is incorporated to electrochemical energy. The potential at which oxidation of the ECL moiety and the species forming a strong reductant occurs depends upon the exact chemical structures thereof, as well as factors such as the pH of the system and the nature of the electrode used to introduce electrochemical energy. It is well known to those of ordinary skill in the art how to determine the optimal potential and emission wavelength of an electro¬ chemiluminescent system. Certain preferred methods of stimulating the ECL system are disclosed in PCT published application US 89/01814, the contents of which are incorporated herein by reference.
Apparatus for Measuring Electrochemiluminescence
Apparatus for carrying out the assays of the invention is shown in Figs. 1, 2, 3, 5, 7, 8 and 9. Fig. 8 discloses an advantageous ECL apparatus. The method may be employed in other types of ECL apparatus which include a working electrode or other triggering surface to provide electrochemical energy to trigger the ECL moiety into electrochemiluminescence, and the plurality of north-south magnets. While the methods of the invention can be carried out in a static or flow-through mode, apparatus 10 includes a flow-through cell, which provides distinct advantages for many types of samples including binding assay samples. Further details of apparatus for carrying out the ECL assays of the invention are disclosed in published PCT applications US 89/04854 and U.S. 90/01370.
Apparatus 10 includes an electrochemical cell 12, a light detection/measurement device 14, which may advantageously be a photomultiplier tube (PMT) , photodiode, charge coupled device, photographic film or emulsion or the like, and a pump 16, which is advantageously a peristaltic pump, to provide for fluid
transport to, through and from cell 12. Alternatively, a positive displacement pump may be used. A shutter mechanism 18 is provided between cell 12 and PMT 14 and is controllably operated to open only so far as to expose PMT 14 to cell 12 during ECL measurement periods. The shutter mechanism may be closed, for example, during maintenance. Also included in apparatus 10 but not illustrated in Fig. 8 is a lightproof housing intended to mount the various components therein and to shield PMT 14 from any external light during the ECL measurements.
Cell 12 itself includes a first mounting block 20 through which passes an inlet tube 22 and an outlet tube 24, which may be advantageously constructed of stainless steel. Mounting block 20 has a first, outer surface 26 and a second, inner surface 28 defining one side of a sample-holding volume 30 of cell 12 in which cell 12 holds the cleaning and/or conditioning and/or measurement solutions during corresponding operations of apparatus 10. Inlet and outlet tubes 22, 24 pass through mounting block 20 from outer surface 26 to inner surface 28 and open into sample-holding volume 30. A second mounting block 32, advantageously constructed of stainless steel also has a first, outer surface 34 and a second, inner surface 36. Second mounting block 32 is separated from first mounting block 20 by an annular spacer 38, advantageously constructed of Teflon or other non-contaminable material. Thus, outer surface 34 of mounting block 32 defines part of the second side of the sample-holding volume 30. Spacer 38 has an outer portion 40 and a central aperture 42 whose inner edge 44 defines the side wall of sample-holding volume 30. Outer portion 40 seals the inner surface 28 of first mounting block 20 to outer surface 34 of second mounting block 32 to prevent any solution from passing out from sample-holding volume 30 between the two surfaces 28, 34. Mounting block 32 further has a central aperture 46 in which a window 48 is seal-fitted to define the rest of the second
side of sample-holding volume 30 as a continuation of outer surface 34. Window 48 is formed of a material which is substantially transparent at the wavelength of electrochemiluminescent light emitted by the ECL moiety. Window 48 is therefore advantageously formed of glass, plastic, quartz or the like.
Inlet tube 22 intersects sample-holding volume 30 at a first end 50 thereof adjacent to spacer 38 and outlet tube 24 intersects sample-holding volume 30 at a second end 52 thereof, adjacent spacer 38. The combination of inlet tube 22, sample-holding volume 30 and outlet tube 24 thereby provides a continuous flow path for the narrow, substantially laminar flow of a solution to, through and from cell 12. Arrows A and B represent the flow into and out of inlet tube 22 and outlet tube 24, respectively.
Mounted on inner surface 28 of first mounting block 20 is a working electrode system 54 which, in the illustrated embodiment, includes first and second working electrodes 56 and 58. In other embodiments, a single working electrode may advantageously be provided, or only electrode 56 may be a working electrode. Working elec¬ trodes 56, 58 are where the electrochemical and ECL re¬ actions of interest can take place. Working electrodes 56, 58 are solid voltammetric electrodes and may therefore be advantageously constructed of platinum, gold, carbons or other materials which are effective for this purpose. Wire connectors 60, 62 connected to working electrodes 56, 58, respectively, pass out through first mounting block 20. Positioned vertically below the horizontally oriented electrode 56 or electrodes 56, 58 are a plurality of magnets 27/37 in north-south orientation as shown in Figs, l and 2 and which are discussed in more detail below; see also Figs. 3, 5 and 7 and discussion thereof below.
Connectors 60, 62 are both connected to a first, "working electrode" terminal 64 of a voltage
SUBSTITUTE SHξET
control 66, illustrated in Fig. 9. Voltage control 66 advantageously operates in the manner of a potentiostat to supply voltage signals to working electrodes 56, 58 and optionally to measure current flowing therefrom during an ECL measurement. Alternatively, connectors 60, 62 may be connected to separate terminals of voltage control 66 for individual operation.
The potentiostat operation of voltage control
66 is further effected through a counter electrode 68 and, optionally but advantageously, a reference electrode
70. In the illustrated embodiment, mounting block 32 is made of stainless steel and counter electrode 68 consists in exposed surfaces 72, 74 of mounting block 32. Counter electrode 72, 74 and working electrodes 56, 58 provide the interface to impress the potential on the solution within sample-holding volume 30 which energizes the chemical reactions and triggers electrochemiluminescence in the sample and/or provides energy for cleaning and conditioning the surfaces of cell 12. Counter electrode 72, 74 is connected by a wire connector 76 to a second,
"counter electrode" terminal 78 of voltage control 66.
Reference electrode 70 provides a reference voltage to which the voltage applied by the working elec¬ trodes 56, 58 is referred, for example, +1.2 volts versus the reference. Reference electrode 70 is advantageously located in outlet tube 24 at a position 80 spaced from cell 12 and is connected through a wire connector 82 to a third "reference electrode" terminal 84 of voltage control 66. In the three electrode mode, current may not flow through reference electrode 70. Reference electrode 70 may be used in a three electrode mode of operation to provide a poised, known and stable voltage and is therefore advantageously constructed of silver/silver chloride (Ag/AgCl) or is a saturated calomel electrode (SCE) . Voltage control 66 may be operable in a two electrode mode of operation using only working electrode 56 and electrode 58 as a
counter/reference electrode. In this two electrode mode of operation, counter/reference electrode 58 is electrically connected to voltage control terminals 78 and 84 on voltage control 66. In this case, voltage control 66 operates essentially as a battery. Voltage control 66 supplies voltage signals to working and counter electrodes 56 and 58 and optionally measures the current flowing through the respective electrodes. Reference electrode 70 may alternatively be a so-called "quasi-reference" electrode constructed of platinum, gold, stainless steel or other material, which provides a less stable voltage, yet one that is measurable with respect to the solution in contact. In both the two and three electrode mode, the reference electrode 70 or 58 serves the purpose of providing a reference against which the voltage applied to working electrodes 56 is measured. The poised voltage reference is currently considered to be more advantageous. Voltage control 66 in its potentiostat operation controls the various electrodes by providing a known voltage at working electrodes 56, 58 with respect to reference electrode 70 while measuring the current flow between working electrodes 56, 58 and counter electrode 72, 74. Potentiostats for this purpose are well known, and the internal structure of voltage control 66 may therefore correspond to any of the conventional, commercially available potentiostats which produce the above-recited functions and so do not form a part of the present invention per se. Indeed, apparatus 10 may alternatively be constructed without an internal voltage control 66, and may be adapted to be connected to an external potentiostat which is separately controlled for providing the required voltage signals to electrodes 56, 58, 72, 74 and 70. These voltage signals, applied in a specific manner as described below, provide repeatable initial conditions for the surfaces of working electrodes 56, 58 and advantageously for the surfaces of cell 12 as a whole, a feature which contributes significantly to
improved precision in ECL measurements.
Pump 16 is advantageously positioned at outlet tube 24 to "pull" solution from a sample volume in the direction of arrow A into inlet tube 22. The solution will flow through inlet tube 22, sample-holding volume 30 and outlet tube 24 past reference electrode 70 and out in the direction of arrow B. Alternatively, pump 16 may be positioned at inlet tube 22 to "push" the solution through apparatus 10. Advantageously, this same flow path through inlet tube 22, sample-holding volume 30 and outlet tube 24 is used for all solutions and fluids which pass through cell 12, whereby each fluid performs a hydrodynamic cleaning action in forcing the previous fluid out of cell 12. Pump 16 may be controlled to suspend its operation to hold a particular solution in cell 12 for any period of time.
The flow-through construction of apparatus 10 permits working electrodes to be impressed with a variable voltage or to be continuously held at a preoperative potential while being continuously exposed to one or more solutions without exposing working electrodes 56, 58 (or counter and reference electrodes
72, 74, 70) to air. Exposure to air, which opens the circuit to the reference electrode 70, permits unknown, random voltage fluctuations which destroy the reproducibility of surface conditions on working electrodes 56, 58. The flow-through construction permits the rapid alternation between initializing steps, in which electrode system 54 is cleaned and conditioned, and measurement steps, in which one or more measurement waveforms or sweeps trigger ECL.
In the practice of the method and use of the apparatus of the invention, reagent compositions are used. The reagent compositions are the components of the assay systems of the invention, i.e., (a) electrolyte, (b) label compound containing an ECL moiety, (c) particles, including magnetically responsive particles,
SUBSTITUTESHEET
(d) analyte of interest or an analog of the analyte of interest, (e) a binding partner of the analyte of interest or of its analog, (f) a reactive component capable of reacting with (d) or (e) , (g) a reductant, or (h) an electrochemiluminescence-reaction enhancer. The reagents may be combined with one another for convenience of use, i.e., two component, three component, and higher multiple component mixtures may be prepared, provided that the components are not reactive with one another during storage so as to impair their function in the intended assay. Desirably, the reagents are two- component or multicomponent mixtures which contain particles as well as one or more other components.
Description of Preferred Embodiments of the Invention
While a wide range of particles can be employed in the particle-based assays of the invention, generally the particles are magnetically responsive or include magnetically responsive particles; and have a density of from 1.0 to 5.0 g/mL and preferably have a density of from 1.1 to 2 g/mL. Choice of the optimum density is within the skill of the art, the rate of settling in gravity-driven assays being a trade-off between the speed of the assay and the desire to create a uniform layer of complex on the electrode surface.
Particles having a wide range of mean diameters can also be employed. Particles having a mean diameter of from 0.001 to 200 μm such as 0.05 to 200 μm can be used; and preferably the particles have a mean diameter of from 0.01 to 10 μm.
Wide ranges of concentration of particles in the assay composition can also be employed. For example, the concentration can range from 1 to 10,000 μg/mL to preferably from 5 to 1000 μg/mL. Desirably, the density of the particles, their size and their concentration is selected such that the particles settle at a rate of at least 0.5 mm/min and preferably at a faster rate.
The art has described a number of magnetic particles which can be used in the assays of the invention. For example, U.S. Patent No. 4,628,037, 4,695,392, 4,695,393, 4,698,302, 4,554,088, U.K. Patent Application GB 2,005,019A and EP 0,180,384, all of which are hereby incorporated herein by reference, describe a variety of magnetic particles which can be used with success. The particles may be paramagnetic or ferromagnetic and may be coated with various materials to which binding compounds are coupled so that the magnetic particle can be used in immunoassays. Desirably the magnetic particles used in the invention have a susceptibility of at least 0.001 cgs units and desirably the susceptibility is at least 0.01 cgs units. The magnetic particles may have a broad range of densities, i.e. from substantially less than that of water, 0.01, to 5 g/mL and preferably from 0.5 to 2 g/mL. The particle sizes can range from 0.001 to 200, such as 0.001 to 100 or 0.05 to 200 μm and preferably from 0.01 to 10 μm. The concentration of the particles may range broadly from 1 to 10,000 μg per mL and preferably is from 5 to 1000 μg per mL.
Desirably the magnetic particles which are used have a low magnetic resonance, as described for example EP 0,180,384, so that after the magnetic field is removed from the electrode surface, the particles demagnetize and can be swept out of the assay cell. Desirably the density, concentration and particle size of the magnetic particles is chosen such that the settling time is at least 0.5 mm/min and desirably it is above that rate. In operation of the magnetic cell it is often desirable to remove the magnet means from the electrode surface prior to inducing electrochemiluminescence in order not to interfere with the operation of the photomultiplier tube. Assays
A variety of assays can be performed using the methods of the invention. These are described in more
detail in the following Examples.
The following non-limiting Examples are given by the way of illustration and are not to be considered a limitation of this invention, many apparent variations of which are possible without departing from the spirit or scope thereof.
EXAMPLES Instrumentation. Materials, and Methods (1) Instrumentation
A flow-through apparatus, as generally shown in
Figs. 1, 2, 3, 5, 7, 8 and 9, employing three electrodes, as described in Figs. 8 and 9, and particularly having the plurality of north-south magnets described in Figs. 1 and 2, is used.
Working Electrode — Au disk, 3 mm diameter Counter Electrode — Au disk, 3 mm diameter Reference Electrode — Ag/AgCl Teflon Gasket (0.15"thick) Plexiglas Faceplate
Inlet Tubing = .042" id polypropylene Aspiration Rates:variable from 0.01 to 5 mL/min Potentiostat: microprocessor controlled Luminometer using Hamamatsu R374 PMT (low gain red sensitive tube) ; PMT Voltage variable 0-1400 V (2) Materials
(a) ECL Label: Ru(bpy)3 2+
(b) ECL Buffer: 112 mM KH2P04, 88 mM
K2HP04-3H20, 50 μM NaCl, 6.5 mM NaN3, 0.8 μM Triton X-100, 0.4 mM Tween 20, 100 mM tripropylamine in H20
(c) ECL Diluent: 37.5 mM KH2P04, 109.2 mM
K2HP04'3H20, 151.7 mM NaCl, 0.65 mM NaN3, 0.43 mM bovine serum albumin in H20
(d) Ru(bpy)3 2+-NHS: Ru(2,2'-bipyridyl)2(4-[3-(1,3-
dioxolan-2-yl)propyl]-4'- methyl-2,2'-bipyridine)2+ (e) Dynal Particles:
(i) Dynal M-450 Dynabeads, 4.5 μm diameter superparamagnetic particles, 30 mg/mL, obtained from Dynal, 45 North Station Plaza, Great Neck, NY 11021 (ii) Dynal M-280 Dynabeads, 2.8 μM diameter superparamagnetic particles, 10 mg/mL, obtained for Dynal, 45 North
Station Plaza, Great Neck, NY 11021 (3) ECL Measurement Cycle (three electrode cell operation)
The ECL measurement cycle consists of three steps: (l) preconditioning, (2) measuring, and (3) cleaning. The preconditioning step involves the application of a voltage triangle wave of 0.0 V to
+2.2 V to -1.0 V to +0.6 V at 2.0 V/sec. The measurement step involves the application of a triangle waveform from +0.6 V to +2.8 V to +2.0 V at 1.0 V/s. The cleaning step involves the application of a voltage square wave from +0.0 V to
+3.0 V to -0.5 V to 0.0 V. All voltages are relative to the Ag/AgCl reference electrode.
EXAMPLE 1 ECL Apparatus and Method for Deposition of Microparticles. Magnetic Collection using a Sedimentation Cell. A cell such as a sedimentation cell for conduct of an assay using magnetic force generated by the plurality of north-south magnets of Figs. 1 and 2 to cause the microparticulate to settle is shown in Fig. 3. Reference numeral 48 refers to a transparent window, reference numeral 122 to a gasket, reference numeral 22 to the inlet in the cell block, reference numeral 56, 58 to the working electrode, reference
numeral 24 to the sample outlet, reference numeral 20 to the cell block itself and reference 27 to the plurality of electromagnets, as shown in Figs. 1 and 2. The plane of the cell block is oriented horizontally; the plurality of magnets 27 is vertically below the magnets. Labeled microparticles (Dynal) in ECL buffer are drawn to the cell by means of a peristaltic pump. The pump is turned off after the microparticles reach the cell. The microparticles in the cell chamber are drawn to the working electrode by means of a magnetic field generated using a plurality of north-south electromagnets as shown in Figs. 1 and 2 and shown generally in Fig. 3 as number 27, which for instance operate at 12 volts and 1.5 amps. By application of the electromagnets, the rate of deposition of microparticles is greatly increased over that observed when the microparticles settle solely due to the force of gravity. This is shown in Fig. 4.
EXAMPLE 2
ECL Apparatus and Method for Deposition of Microparticles. Magnetic Collection using a Collection Cell.
An assay is carried out in a cell such as a collection cell as described in Fig. 5. With reference to Fig. 5, reference numeral 48 refers to transparent window, reference numeral 132 to a gasket, reference numeral 22 to an inlet in the cell block, reference numeral 56, 58 to a working electrode, reference numeral 20 to the cell block itself, reference numeral 24 to the sample outlet and reference numeral 37 to a plurality of permanent magnets as shown in Figs. 1 and 2.
The plane of the cell block is oriented horizontally; the plurality of magnets 37 is vertically below the magnets. Labeled microparticles (Dynal) in ECL buffer are drawn to the electrochemical cell by
SHEET
means of a peristaltic pump. Prior to the sample introduction, permanent magnets 37 are positioned immediately below the working electrode/solution interface at a distance of 0.035 inches. As the sample is being drawn to the cell, the microparticles deposit onto an area over the working electrode, as defined by the area of the magnets. The pump is turned off and the magnetic field withdrawn after the entire sample is deposited. The longer the collection time, the more particles are deposited. Increasing the concentration of particles on the working electrode results in an increased ECL intensity as shown in Fig. 6.
EXAMPLE 3 Use of Maσnet for Deposition of Microparticles.
Magnetic Field Orientation. Microparticles 96 which are attracted to a plurality of magnets 27/37 as shown in Figs. 1 and 2, whether they be permanent magnets or electromagnets, align with the orientation of the magnetic field 98, such as in Fig. 7 which depicts magnetic field 98 and the resultant particle arrangement 96 which is parallel to the surface of the working electrode 56/58, in the vicinity of that surface. Figs. 1 and 2 schematically show a cell and magnets 27/37 of Figs. 3, 5, 7, 8 and 9 which is equipped with a magnet system which advantageously imposes field lines which are largely parallel to the plane of the electrode surface 56, 58. The magnet system consists of a plurality of individual permanent or electromagnets which are stacked and oriented such that the north and south poles of the magnets 27/37 alternate in the stack. The individual magnets of magnets 27/37 are separated by air or any non- magnetically responsive material. The arrangement as shown in Figs. 1 and 2 advantageously applies magnetic lines of force to the region above the working
electrode which are nearly horizontal to the plane of the electrode. This induces an orientation of the magnetically responsive particles in which the particles lie upon the surface of the electrode and are readily accessible to the electrochemical energy supplied by the electrode; see Fig. 7.
The magnet system 27/37 shown in Figs. 1 and 2 also is advantageous in that the magnetic field lines do not extend a long distance from the magnet structure; see Fig. 7. The magnetic field from such a magnet system is not likely, therefore, to induce permanent magnetic behavior on ferromagnetic materials near the electrode apparatus and will not severely affect the operation of a photomultiplier tube near the flow cell apparatus.
EXAMPLE 4
Coating of Particles With Labeled Non-specific Protein at Moderate Surface Concentration 30 mg (1 ml) of 4.5 μm uncoated magnetically responsive, polystyrene M-450 DYNABEADS (DYNAL, Oslo, Norway) were washed by magnetic separation with a 150 mM phosphate buffer pH 7.5 solution using 2 ml/wash. 150 μg of Ru(bpy)3 2+-labeled mouse IgG (Jackson Immunochemicals) in 1 ml of phosphate buffer saline (PBS) with 0.05% thimerasol were added to the particles. This mixture was allowed to incubate overnight at room temperature with rotation. The solution was then magnetically separated from the particles and removed. To block unreacted sites, 1 ml of 3% BSA/PBS with 0.05% sodium azide was added to the particles, and the resultant solution was allowed to incubate 2 hours at room temperature. The particles were washed 5 times (2 ml/wash) , and then finally resuspended in 6 ml of the same buffer for storage.
E SHEET
EXAMPLE 5 Electrochemiluminescent (ECL) Measurement Using Magnetically Responsive Particles Uniform and nonuniform, polymeric and non- polymeric, magnetically responsive particles (Dynal, Oslo, Norway; Polysciences, Warrington, PA 18976; Cortex Biochem, San Leandro, CA 94577; Aldrich, Milwaukee, WI 53201) were coated with labeled proteins as described in Example 4. The coated particles were washed with ECL buffer three times before making 2 mL of a 300 μg/mL suspension. Using a peristaltic pump, 500 μl of the particle suspension is drawn into the flow cell (Example 2) . As the particles flow to the working electrode, they are attracted and concentrated onto the working electrode surface by the magnets. Electrochemiluminescence using the magnetic particles is measured using a Hamamatsu R374 photomultiplier tube centered above the flow cell where particles concentrate on the working electrode surface. Table I shows representive ECL photoemission levels obtainable from the labeled-protein coated magnetically responsive particles.
Table I. CL Measurements from Different
EXAMPLE 6 Preparation of Physically Adsorbed Sheep Anti-Thyroid Stimulating Hormone (TSH) Coated Dynal Particles
(REAGENT Ii ImL of 4.5μm uncoated magnetic, polystyrene particles with -OH residues on their surface (DYNAL, DYNABEADS M-450, DYNAL A.S. Oslo, Norway) was washed by magnetic separation with a 150mM sodium carbonate / bicarbonate pH 9.6 solution using 2 mL/wash. 0.5mg of affinity purified Sheep anti-TSH, HCG scrubbed antibody (CIBA) in 1 mL of the carbo/bicarbo solution was added to the particles. This mixture was incubated overnight at room temperature with mixing. The solution was then magnetically separated from the particles and removed. ImL of 3% BSA/PBS w/ 0.05% sodium azide was added and incubated 2 hours at room temperature with agitation to block unreacted sites. The particles were washed 5 times (2mL/wash) then finally resuspended in ImL of the same buffer for storage. The final concentration of Bead Reagent I was 3% by weight.
EXAMPLE 7 Preparation of Ouabain-BSA Conjugate (REAGENT II) ACTIVATION OF OUABAIN:
60.4mg of ouabain octahydrate (Aldrich Cat# 14,193-3) in 6mL of deionized (di) H20 (wrapped in foil) was mixed with 87mg of sodium metaperiodate (Mallinckrodt Cat# 1139) and the mixture was incubated at room temperature for 2 hours, rotating. The reaction was terminated by passing the reaction mixture through Dowex 1 X 8 - 50 ion exchange resin (Aldrich Cat# 21,740-9) with diH20. 200μL 1M sodium phosphate pH 7.2 was added to adjust the pH of the solution to 7.0.
CONJUGATION OF ACTIVATED OUABAIN TO BSA: 50mg of activated ouabain(4.6mL) was then added dropwise to 108mg bovine serum albumin BSA, Miles Fraction V) in 5mL 0.15M PBS pH 7.8. This is a 40:1 (OUABIN:BSA) ratio. The reaction was incubated at room temperature for 2 hours, mixing, followed by rapid addition of 30mg of sodium cyanoborohydride while mixing. Free ouabain and excess sodium cyanoborohydride were removed by dialysis at 4°C in 0.15M PBS w/ 0.05% sodium azide pH 7.8. The
Ouabain-BSA Conjugate Reagent II was stored at 4°C.
EXAMPLE 8 Preparation of Physically Adsorbed Ouabain-BSA Coated Dynal Particles
(REAGENT III) 5mg of 4.5μm uncoated magnetic, polystyrene particles with -OH residues on their surface (DYNAL, DYNABEADS M-450, DYNAL A.S. Oslo, Norway) were washed by magnetic separation with a 150mM sodium carbonate / bicarbonate pH 9.6 solution using lOmL/wash. 3mg of Ouabain-BSA conjugate (Conjugate Reagent II) in 5 mL of the carb/bicarb solution was added to the particles. This mixture was incubated overnight at room temperature while rotating. The solution was then magnetically separated from the particles and removed. 5mL of 3% BSA/PBS w/ 0.05% sodium azide was added and incubated 2 hours at room temperature, rotating to block unreacted sites. The particles were washed 5 times (lOmL/wash) then finally resuspended in ImL of the same buffer for storage. The final concentration of Bead Reagent III was 3% by weight.
EXAMPLE 9 Preparation of Ru(bpy>3 2+-Labeled Mouse Anti-Digoxin
(REAGENT IV) lmg of mouse anti - Digoxin (Cambridge Medical Technologies Cat# 200-014 Lot A3575) was labeled with Ru(bpy)3 2+. The monoclonal antibody (MAb) anti Digoxin antibody was buffer exchanged using Centricon 30 microconcentrators (Amicon) into 0.15M potassium phosphate buffer, 0.15M NaCl pH 7.8, the final volume being 0.5mL. Immediately prior to use, 0.5mg of Ru(bpy)3 2+-NHS was dissolved with 125μL of anhydrous dimethyl sulfoxide (Aldrich) . To achieve a 25:1 molar ratio of Ru(bpy)3 2+ to protein based on molecular weights of 1057 and 150,000 respectively, 0.18mg Ru(bpy)3 2+-NHS (45μL) was added to the protein solution while shaking. The reaction tube was incubated in the dark at room temperature, 30 minutes, while shaking. The reaction was terminated by the addition of 25μL of 1M glycine and incubated for 10 minutes. The reaction mixture was purified by passage through a Sephadex G - 25 column (1 X 20cm in 0.15M potassium phosphate, 0.15M NaCl with 0.05% sodium azide pH 7.2). The Ru(bpy)3 2+-labeled mouse anti-digoxin fractions were collected and pooled. The labeled protein (Reagent IV) was determined to have 12 labels per protein molecule.
EXAMPLE 10 Preparation of Ru(bpy)3 2+-Labeied Mouse Anti-Thyroid Stimulating Hormone (TSH)
(REAGENT V) 0.5mg of mouse anti -TSH (CIBA) was labeled with Ru(bpy)3 +. The MAb anti TSH antibody was buffer exchanged using Centricon 30 microconcentrators (Amicon) into 0.15M potassium phosphate buffer, 0.15M NaCl pH 7.8, the final volume being 0.35mL. Immediately prior to use, 0.5mg of Ru(bpy)3 2+-NHS was
UBSTITUTE SHEET
dissolved in 75μL of anhydrous dimethyl sulfoxide (Aldrich). To achieve a 50:1 molar ratio of Ru(bpy)3 2+ label to protein based on molecular weights of 1057 and 150,000 respectively, 0.176mg Ru(bpy)3 2+-NHS (26.4μL) was added to the protein solution while shaking. The reaction tube was incubated in the dark at room temperature, 30 minutes, while shaking. The reaction was terminated by the addition of 25μL of 1M glycine and incubated for 10 minutes. The reaction mixture was purified by passage through a Sephadex G - 25 column (1 X 20σm in 0.15M potassium phosphate, 0.15M NaCl with 0.05% sodium azide pH 7.2). The Ru(bpy)3 2+-labeled mouse anti- TSH fractions were collected and pooled. The labeled protein (Reagent V) was determined to have 14 labels per protein.
EXAMPLE 11 One Step Separation Sandwich Assay for Thyroid Stimulating Hormone (TSH) lOOμL serum calibrators (London Diagnostics
TSH LumiTAG Kit), 25μL Ru(bpy)3 2+-labeled mouse anti-TSH (Reagent V) in ECL buffer and 25μL Sheep anti-TSH-DYNAL particles (Reagent I) in ECL buffer were combined and incubated in polypropylene tubes for 15 minutes, at room temperature, with mixing. The particles were then washed by magnetic separation and then resuspending the particles in 500μL of ECL buffer. This wash procedure was repeated two additional times. Finally, the particles were resuspended in ImL of ECL buffer. The electrochemiluminescence (ECL) for each sample is read as described in Example 2. The ECL counts are directly proportional to the concentration of analyte present in the sample (increasing counts as the concentration of analyte increases) . Table II demonstrates a representative assay curve.
Table II .
One-Step Separation Sandwich Assay: Detection of TSH
TSH Concentration WmL) 0.00
0.05
0.10
0.50
2.50 10.0
25.0
EXAMPLE 12 One Step Non Separation Sandwich Assay for Thyroid
Stimulating Hormone (TSH) lOOμL serum calibrators (London Diagnostics TSH LumiTAG Kit), 25μL Ru(bpy)3 2+-labeled mouse anti-TSH (Reagent V) in ECL buffer and 25μL Sheep anti-TSH-DYNAL particles (Reagent I) in ECL buffer were combined and incubated in polypropylene tubes for 15 minutes, at room temperature, with mixing. Prior to reading results, ImL of ECL buffer was added. The electrochemiluminescence (ECL) for each sample is read as described in Example 2. The ECL counts are directly proportional to the concentration of analyte present in the sample (increasing counts as the concentration of analyte increases) . Table III demonstrates a representative assay curve.
UBSTITUTE SHEET
Table III. - - e tion Sa dw c s :
50μL serum calibrator (TDx Assay, Abbott Labs, Chicago, IL) and 25μL Ru(bpy)3 2+-labeled mouse anti-digoxin (Reagent IV) in ECL buffer, were combined and incubated 20 minutes at room temperature with mixing. 25μL Ouabain-BSA-DYNAL particles (Reagent III) in ECL buffer was added and incubated an additional 20 minutes, at room temperature, with mixing. The particles were then washed by magnetic separation and then resuspending the particles in 500μL of ECL buffer. This wash procedure was repeated two additional times. Finally, the particles were resuspended in ImL of ECL buffer. The electrochemiluminescence (ECL) for each sample is read as described in Example 2. The ECL counts are inversely proportional to the concentration of analyte present in the sample (decreasing counts as the concentration of analyte increases) . Table IV demonstrates a representative assay curve.
Table IV.
Two-Step Separation Competitive Assay:
Detection of Digoxin
Digoxin Concentration ECLCounts (nq/mL) (Duplicate Samples)
0.0 22031 21154
0.5 13367 13638
1.0 9506 9607
2.0 5244 5129 3.0 2959 2994
5.0 1581 1631
EXAMPLE 14 Two Step Non Separation Competitive Assay for Digoxin 50μL serum calibrator (TDx Assay, Abbott
Labs, Chicago, IL) and 25μL Ru(bpy)3 2+-labeled mouse anti-digoxin (Reagent IV) in ECL buffer, were combined and incubated 20 minutes at room temperature with mixing. 25μL Ouabain-BSA-DYNAL particles (Reagent III) in ECL buffer was added and incubated an additional 20 minutes, at room temperature, with mixing. Prior to reading, the particles were resuspended in ImL of ECL buffer. The electrochemiluminescence (ECL) for each sample is read as described in Example 2. The ECL counts are inversely proportional to the concentration of analyte present in the sample (decreasing counts as the concentration of analyte increases) . Table V demonstrates a representative assay curve.
Table V.
Two-Step Non-Separation Competitive Assay:
Detection of Digoxin
Digoxin Concentration ECL Counts (ng/mL) (Duplicate Samples)
0.0 42051 39643
0.5 28721 28074
1.0 22190 21364
2.0 14660 14542 3.0 11315 11893
5.0 9161 8945
EXAMPLE 15 Two Step Non Separation Competitive Assay for Digoxin Using a Read Cycle With Additional Washing of Final
Reaction Sample on the Electrode 50μL serum calibrator (TDx Assay, Abbott Labs, Chicago, IL) and 25μL Ru(bpy)3 2+-labeled mouse anti-digoxin (Reagent IV) in ECL buffer, were combined and incubated 20 minutes at room temperature with mixing. 25μL Ouabain-BSA-DYNAL particles (Reagent III) in ECL buffer was added and incubated an additional 20 minutes, at room temperature, with mixing. Prior to reading, the particles were resuspended in ImL of ECL buffer. The electrochemiluminescence (ECL) for each sample is read as described in Example 2. The ECL counts are inversely proportional to the concentration of analyte present in the sample (decreasing counts as the concentration of analyte increases) . Table VI demonstrates a representative assay curve.
EXAMPLE 16 Preparation of Nucleic Acid Magnetic Particles And ECL Use Dynal M 450 particles were activated with 2- fluoro-1-methylpyridinium toluene-4-sulfonate using standard procedures (6) . These activated particles
were then reacted with oligonucleotides JK8 and JK8C.
Table VI.
Two-Step Separation Competitive Assay:
Detection of Digoxin Digoxin Concentration ECLCounts
(nq/mU (Duplicate Samples)
0.0 42613 35309
0.5 24211 24168
1.0 17561 17206 2.0 10491 9909
3.0 6712 7145
5.0 4680 4603
To 100 mg of activated Dynal particles were added 33 nmoles of oligonucleotide in 650 μl of 0.1M NaHC03 followed by incubation for 3 hours with mixing. The particles were blocked by the addition of ethanolamine (4mL, 0.1M). The coupled particles were mixed with 0.5mg/mL single stranded salmon sperm DNA in ECL buffer, washed 4-5 times into ECL buffer and resuspended at lOmg/mL in ECL buffer containing lOOμg/mL single stranded salmon sperm DNA.
The ability to detect ECL after hybridization to particles is demonstrated by the hybridization of particles coupled to JK8 and JK8C with Ru(bpy)3 2+-label oligonucleotide JK7; JK7 is complementary to the JK8 sequence and not complementary to the JK8C sequence. Individual lots of particles (300 μg) in ECL buffer are mixed with 50 μl of ECL buffer containing 12.5, 6.3, 3.01 and 1.5 fmoles of label JK7. These mixtures are hybridized for 4 hours at 52°C followed by washing with ImL ECL buffer and then resuspension on 830 μl of ECL buffer. The samples are analyzed as described in Example 2. At 12.5 fmoles the JK8 particles display over 1000 times more ECL counts than the HK8C particles; at 6.3 fmoles the JK8 particles display nearly 1000 times more ECL counts than the JK8C
particles; and, at 3.02 and 1.5 fmoles, the JK8 particles display about 5 and about 3 times more ECL counts than the JK8C particles respectively. This demonstrates the ability to detect by specific hybridization the presence of specific sequences directly immobilized on the surface of particles by ECL.
EXAMPLE 17 Preparation of Streptavidin Magnetic Particles I
Dynal M 450 particles were activated with 2- fluoro-1-methylpyridinium toluene-4-sulfonate using standard procedures (6) . The activated particles were then reacted with streptavidin (Sigma Ltd) . Activated particles (50mg) were washed with 0.1M NaHC03 followed by the addition of streptavidin (1.5mg) and reacted overnight. The particles were blocked by the addition of ethanolamine (4mL, 0.1M). The coupled particles were mixed with 0.5mg/mL single stranded salmon sperm DNA in ECL buffer, washed 4-5 times into ECL buffer and resuspended at lOmg/mL in ECL buffer containing lOOμg/mL single stranded salmon sperm DNA. The streptavidin particles from Dynal M-280 also proved valuable but gives lower signals with the current assay sequence. For immunoassay applications particles were blocked with BSA after antigen or antibody coupling using the buffers used for passive coating.
EXAMPLE 18 Preparation of Streptavidin Magnetic Particles II
To 15 mg of BSA (in 2-3 mL PBS) , 105 μl of dimethylsulfoxide containing 50 mg/mL of biotin-x-NHS (Clontech, San Diego CA. 5002-1) was added followed by mixing and incubation at room temperature for 30 minutes. The reaction was stopped by adding 30 μl of 1M glycine and incubation at room temperature for 10 minutes. The reaction mix was purified by gel
filtration chromatography (Biorad, Bio-Gel P6) . This biotin-BSA was filtered using 0.2 μm syringe. 5 mg biotin-BSA in 10 mL of 0.2 M sodium carbonate/ bicarbonate buffer pH 9.6 (carbonate/bicarbonate) buffer was added to 300 mg of Dynabeads washed with carbonate/bicarbonate (Dynal 14002) . This mixture was Vortexed, and incubated overnight at room temperature with mixing. These particles were magnetically separated followed by the addition of 10 mL ECL diluent and 100 μl tRNA (10 mg/mL) . This mixture was incubated for 3-4 hours at room temperature with mixing. These particles were washed once with 10 mL of ECL diluent and resuspended in 10 mL of ECL diluent and 100 μl tRNA (10 mg/mL) . This mixture was mixed and incubated at 2- 6 °C overnight to stabilize proteins on particles. The particles were magnetically separated and suspended in 10 mL of PBS containing 15 mg of streptavidin (Scripps S1214) followed by mixing for one hour. The particles were washed 4 times in 10 mL ECL diluent, with 5 minutes mixing for each wash. The particles were finally resuspended in 29.7 mL of ECL diluent and 300 μl tRNA (lOmg/mL) to a final concentration of 10 mg/mL particles + 100 μg/mL tRNA.
EXAMPLE 19
Assay for Specific Genomic DNA Sequences.
The assay format described here makes use of two oligonucleotides, both of which hybridize to the same DNA strand next to each other, one probe allows capture; the other labels the complex (sandwich hybridization) . This assay was demonstrated using E.coli DNA and probes specific for the trp E/D gene region. The E.coli DNA was prepared following standard protocols (1) . The salmon sperm control DNA was purchased from Sigma Ltd. To the samples of DNA were added 14μl of hybridization buffer (10X PBS, lOmMEDTA and 0.7%SDS), 2ng of biotin labeled TRP.C04 and 5ng of
Ru(bpy)3 2+-label TRP.C03. These samples were made up to lOOμl with water. The samples were heated to 97°C and incubated at 97°C for lOmin, cooled to 50°C and hybridized for 2hrs. To these samples we added 20μl of streptavidin coated magnetic particles II and mixed for 2hrs at room temperature. The particles were then washed 4 times in ECL buffer resuspended in 500μl of ECL buffer and are analyzed as described in Example 2. The positive DNA is E.coli and the negative DNA is salmon sperm. The results obtainable are shown in Table VII.
Table VII
These results demonstrate the ability of the ECL assay system to function in the detection of a genomic gene in E.coli using a sandwich hybridization assay format on non amplified DNA. The streptavidin coated magnetic particles I can be similarly used in the fashion that the streptavidin coated magnetic particles II are used in this example.
Have thus described in detail preferred embodiments of the present invention, it is to be understood that the invention defined by the appended claims is not to be limited by particular details set forth in the above description as many apparent variations thereof are possible without departing from the spirit or scope of the present invention.
REFERENCES
1. Beaucage SL, Caruthers MH. Deoxynucleoside phosphoramidites, a new class of key intermediates for deoxypolynucleotide synthesis. Tetradhedron Lett 1982;22:1859-62.
2. Shibata DK, Arnheim N, Martin JW. Detection of human papilloma virus in paraffin-embedded tissue using the polymerase chain reaction. J Exp Med 1988;167:225-30.
3. Yanofsky, C. et al (1981) Nucleic Acids Res. 24, 6647-6668.
4. Updyke TV, Nicolson GL. Immunoaffinity isolation of membrane antigens with biotinylated monoclonal antibodies and streptavidin-agarose. Methods Enzymol 1986;121:717-25.
5. Cardullo RA, Agrawal S, Flores C, Zamecnik DC, Wolf DE. Detection of nucleic acid hybridization by nonradiative fluorescence resonance energy transfer. Proc Natl Acad Sci 1988;85:8790-4.
6. Ngo TT. Procedure for activating polymers with primary and or secondary hydroxyl groups. Makromol Chem Macromol Symp 1988;17:224-39.
7. Coutlee F, Bobo L, Mayur K, Yolken RH, Viscidi RP. Immunodetection of DNA with biotinylated RNA probes: A study of reactivity of a monoclonal antibody to DNA-RNA hybrids. Anal Biochem 1989;181:96-105.
8. Casadei J, Powell MJ, Kenten JH. Expression and secretion of aequorin as a chimeric antibody using a mammalian expression vector. Proc Natl Acad Sci 1990;87:2047-51.
9. Molecular cloning, a laboratory manual 2nd Ed Sambrook, J. Cold Spring Harbor Laboratory New York.
10. Heney G, Orr GA. (1981) Anal Biochem. 114,92-96.
11. Mullis KB, Faloona FA. Specific synthesis of DNA in vitro via a polymerase-catalyzed chain reaction. Methods Enzymol 1987;155:335-50.
12. Lyons J, Janssen JWG, Bartram C, Layton M, Mufti GJ. Mutation of Ki-ras and N-ras oncogenes in myelodysplastic syndromes. Blood 1988;71:1707-12.
13. Saiki RK, Gelfand DH, Stoffel S, Scharf SJ, Higuchi R, Horn GT, Mullis KB, Erlich HA. Primer- directed enzymatic amplification of DNA with a thermostable DNA polymerase. Science 1988;239:487-91.
14. Yee C, Krishnan-Hewlett I, Baker CC, Schlegel R, Howley PM. Presence and Expression of Human Papillomavirus sequences in human cervical carcinoma cell lines. Am J Pathol 1985;119:361-6.
15. Reddy EP, Reynolds RK, Santo E, Barbacid M. A point mutation is responsible for the acquisition of the transforming properties by the T24 human bladder carcinoma oncogene. Nature 1982;300:149- 52.
16. Marmur J. J Mol Biol 1961;3:208.
Claims
1. A method for performing a binding assay for an analyte of interest present in a sample comprising the steps of:
(a) forming a composition containing (i) said sample
(ii) an assay-performance-substance which contains a component linked to a label compound capable of being induced to electrochemiluminesce, and (iii) a plurality of magnetically responsive suspended particles capable of specific binding with the analyte and/or said assay-performance-substance;
(b) incubating said composition to form a complex which includes a particle and said label compound;
(c) introducing said composition into an assay cell;
(d) collecting said complex at the surface of an electrode by imposition of a magnetic field on said particles;
(e) inducing the label compound in said collected complex to luminescence by imposing a voltage on said electrode; and
(f) measuring the emitted luminescence at the electrode surface to measure the presence of the analyte of interest in the sample; wherein a plurality of magnets in north-south orientation are positioned vertically below a horizontally oriented electrode surface.
2. The method of claim 1 wherein the assay iε a homogeneous assay.
3. The method of claim 1 wherein the assay is a heterogeneous assay.
4. The method of claim 3 wherein the assay is heterogeneous by further comprising, after the incubating step (b) and before the measuring step (f) , separating from the complex unbound components of the composition.
5. The method of claim 4 wherein the separating step is before the inducing step (e) .
6. The method of claim 4 wherein the separating step is prior to the introducing step (c) .
7. The method of claim 5 wherein the separating step comprises, after the collecting step (d) , pumping a fluid into the assay cell, said fluid being substantially free of label or label reagents, to thereby wash from the complex any unbound components of the composition.
8. An apparatus for performing a binding assay for an analyte of interest present in a sample based upon measurement of electrochemiluminescence at an electrode surface comprising:
(a) a cell defining an assay sample containing volume and having inlet and outlet means, an electrode, and further including means for obtaining a substantially even distribution of said complex on said electrode surface;
(b) means to impress a voltage upon said electrode; and
(c) means to measure the electrochemiluminescence generated at said electrode; wherein the means for obtaining an even distribution of complex includes means for generating a magnetic field oriented with respect to said electrode so that the lines of force of said magnetic field are substantially parallel with the surface of said electrode in the region of said surface; and, the means for generating a magnetic field includes a plurality of magnets in north-south orientation and separated by non-magnetic material positioned vertically below said electrode.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP4507261A JP3013937B2 (en) | 1991-02-06 | 1992-02-05 | Method and apparatus for a luminescence assay based on magnetic microparticles containing a plurality of magnets |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US65242791A | 1991-02-06 | 1991-02-06 | |
US652,427 | 1991-02-06 | ||
US82726992A | 1992-02-03 | 1992-02-03 | |
US827,269 | 1992-02-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1992014138A1 true WO1992014138A1 (en) | 1992-08-20 |
Family
ID=27096296
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1992/000982 WO1992014138A1 (en) | 1991-02-06 | 1992-02-05 | Method and apparatus for magnetic microparticulate based luminescence assay including plurality of magnets |
Country Status (7)
Country | Link |
---|---|
JP (2) | JP3013937B2 (en) |
CN (1) | CN1107863C (en) |
AU (1) | AU1530492A (en) |
IE (1) | IE69371B1 (en) |
IL (1) | IL100866A (en) |
NZ (1) | NZ241538A (en) |
WO (1) | WO1992014138A1 (en) |
Cited By (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5466416A (en) * | 1993-05-14 | 1995-11-14 | Ghaed; Ali | Apparatus and methods for carrying out electrochemiluminescence test measurements |
US5538687A (en) * | 1994-12-16 | 1996-07-23 | Behringer Mannheim Gmbh | Apparatus for generating optically detectable signals by applying electrical potentials to sample liquids |
US5744367A (en) * | 1994-11-10 | 1998-04-28 | Igen International, Inc. | Magnetic particle based electrochemiluminescent detection apparatus and method |
EP0859230A1 (en) * | 1997-02-10 | 1998-08-19 | Cranfield University | Detection of analytes using electrochemistry |
EP0859229A1 (en) * | 1997-02-10 | 1998-08-19 | Gist-Brocades B.V. | Detection of analytes using electrochemistry |
WO1998041867A1 (en) * | 1997-03-18 | 1998-09-24 | Igen International, Inc. | Detection of water-borne parasites using electrochemiluminescence |
WO1999039206A1 (en) * | 1998-01-30 | 1999-08-05 | Roche Diagnostics Gmbh | Method for analyzing a test sample by means of an electro-chemoluminescence bond reaction test |
WO2000003233A1 (en) * | 1998-07-10 | 2000-01-20 | Imperial College Of Science, Technology And Medicine | Electrochemiluminescence cell with floating reaction electrodes |
US6100045A (en) * | 1997-02-10 | 2000-08-08 | Dsm N.V. | Detection of analytes using electrochemistry |
EP1042508A1 (en) * | 1997-12-23 | 2000-10-11 | Meso Scale Technologies LLC | Methods and apparatus for improved luminescence assays using microparticles |
US6132955A (en) * | 1995-05-18 | 2000-10-17 | Igen International, Inc. | Method for derivitizing electrodes and assay methods using such derivitized electrodes |
US6136268A (en) * | 1999-08-17 | 2000-10-24 | Orion Diagnostica | Method for luminescence measurements |
EP1325333A1 (en) * | 2000-10-10 | 2003-07-09 | Aviva Biosciences Corporation | Individually addressable micro-electromagnetic unit array chips in horizontal configurations |
WO2003096014A2 (en) * | 2002-05-08 | 2003-11-20 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Magneto-controlled method and system for determining an analyte in a liquid medium |
AT413153B (en) * | 2004-03-11 | 2005-11-15 | Christian Doppler Labor Fuer S | METHOD AND DEVICE FOR DETECTING MARKED MICROPARTICLES |
WO2007101661A1 (en) | 2006-03-09 | 2007-09-13 | F.Hoffmann-La Roche Ag | Anti-drug antibody assay |
GB2436616A (en) * | 2006-03-29 | 2007-10-03 | Inverness Medical Switzerland | Assay device and method |
WO2008031532A1 (en) | 2006-09-12 | 2008-03-20 | F. Hoffmann-La Roche Ag | Anti-drug antibody assay |
WO2008104344A1 (en) | 2007-02-27 | 2008-09-04 | F. Hoffmann-La Roche Ag | Method for the assessment of the inhibitory activity of antibodies against insulin-like growth factor i receptor |
WO2009077127A1 (en) | 2007-12-15 | 2009-06-25 | F. Hoffmann-La Roche Ag | Distinguishing assay |
WO2010072384A1 (en) | 2008-12-22 | 2010-07-01 | F. Hoffmann-La Roche Ag | ANTI-IDIOTYPE ANTIBODY AGAINST AN ANTIBODY AGAINST THE AMYLOID β PEPTIDE |
WO2012022774A1 (en) | 2010-08-19 | 2012-02-23 | Roche Diagnostics Gmbh | An assay for measurement of antibodies binding to a therapeutic monoclonal antibody |
WO2012143380A1 (en) | 2011-04-20 | 2012-10-26 | F. Hoffmann-La Roche Ag | Microwaves for immunohistochemical analysis |
WO2012175508A1 (en) | 2011-06-22 | 2012-12-27 | F. Hoffmann-La Roche Ag | Removal of target cells by circulating virus-specific cytotoxic t-cells using mhc class i comprising complexes |
WO2013092611A2 (en) | 2011-12-19 | 2013-06-27 | F. Hoffmann - La Roche Ag | Method for the detection of free binding partner of a multispecific binder |
WO2013113663A1 (en) | 2012-02-01 | 2013-08-08 | F. Hoffmann-La Roche Ag | Method for the detection of a binding partner of a multispecific binder |
WO2013132000A1 (en) | 2012-03-08 | 2013-09-12 | F. Hoffmann-La Roche Ag | Multiplexed chromatography-immunoassay method for the characterization of circulating immune complexes |
EP2573562A3 (en) * | 2007-02-09 | 2013-10-30 | Advanced Liquid Logic, Inc. | Droplet actuator devices and methods employing magnetic beads |
WO2014009474A1 (en) | 2012-07-13 | 2014-01-16 | F. Hoffmann-La Roche Ag | Method for the detection of a multispecific binder |
WO2015000865A1 (en) | 2013-07-04 | 2015-01-08 | F. Hoffmann-La Roche Ag | Interference-suppressed immunoassay to detect anti-drug antibodies in serum samples |
US9414777B2 (en) | 2004-07-13 | 2016-08-16 | Dexcom, Inc. | Transcutaneous analyte sensor |
WO2017072210A1 (en) | 2015-10-29 | 2017-05-04 | F. Hoffmann-La Roche Ag | Anti-variant fc-region antibodies and methods of use |
WO2017093226A1 (en) | 2015-11-30 | 2017-06-08 | F. Hoffmann-La Roche Ag | Immunoassay for the determination of fc-region modified antibodies |
US9986942B2 (en) | 2004-07-13 | 2018-06-05 | Dexcom, Inc. | Analyte sensor |
WO2019105916A1 (en) | 2017-11-29 | 2019-06-06 | F. Hoffmann-La Roche Ag | Target interference suppressed anti-drug antibody assay |
US10501521B2 (en) | 2012-12-21 | 2019-12-10 | Hoffmann-La Roche Inc. | Disulfide-linked multivalent MHC class I comprising multi-function proteins |
US10610135B2 (en) | 2005-03-10 | 2020-04-07 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US10677695B2 (en) | 2002-11-07 | 2020-06-09 | Lsi Medience Corporation | Magnetic material for collecting magnetic particles and utilization thereof |
WO2020141145A1 (en) | 2018-12-30 | 2020-07-09 | F. Hoffmann-La Roche Ag | Anti-rabbit cd19 antibodies and methods of use |
US10813577B2 (en) | 2005-06-21 | 2020-10-27 | Dexcom, Inc. | Analyte sensor |
WO2020229378A1 (en) | 2019-05-13 | 2020-11-19 | F. Hoffmann-La Roche Ag | Interference-suppressed pharmacokinetic immunoassay |
WO2021136772A1 (en) | 2020-01-02 | 2021-07-08 | F. Hoffmann-La Roche Ag | Method for determining the amount of a therapeutic antibody in the brain |
WO2021254926A1 (en) | 2020-06-16 | 2021-12-23 | F. Hoffmann-La Roche Ag | Method for determining the free antigen of an antibody in a sample |
WO2022214565A1 (en) | 2021-04-09 | 2022-10-13 | F. Hoffmann-La Roche Ag | Process for selecting cell clones expressing a heterologous polypeptide |
WO2023021055A1 (en) | 2021-08-19 | 2023-02-23 | F. Hoffmann-La Roche Ag | Multivalent anti-variant fc-region antibodies and methods of use |
WO2023117325A1 (en) | 2021-12-21 | 2023-06-29 | F. Hoffmann-La Roche Ag | Method for the determination of hydrolytic activity |
WO2024044622A1 (en) | 2022-08-24 | 2024-02-29 | Amgen Inc. | Anti-drug antibody assays |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07271865A (en) | 1994-04-01 | 1995-10-20 | Mitsubishi Corp | Method for managing copyright of data base |
US6744894B1 (en) | 1994-04-01 | 2004-06-01 | Mitsubishi Corporation | Data management system |
US7036019B1 (en) | 1994-04-01 | 2006-04-25 | Intarsia Software Llc | Method for controlling database copyrights |
US6424715B1 (en) | 1994-10-27 | 2002-07-23 | Mitsubishi Corporation | Digital content management system and apparatus |
EP1691316A1 (en) | 1994-10-27 | 2006-08-16 | Intarsia Software LLC | Data copyright management system |
DE69532434T2 (en) | 1994-10-27 | 2004-11-11 | Mitsubishi Corp. | Device for file copyright management system |
US8595502B2 (en) | 1995-09-29 | 2013-11-26 | Intarsia Software Llc | Data management system |
US7801817B2 (en) | 1995-10-27 | 2010-09-21 | Makoto Saito | Digital content management system and apparatus |
JP4763866B2 (en) | 1998-10-15 | 2011-08-31 | インターシア ソフトウェア エルエルシー | Method and apparatus for protecting digital data by double re-encryption |
DE60027578T2 (en) * | 1999-07-16 | 2007-01-25 | WM. Marsh Rice University, Houston | Method of detecting bioanalytes using metallic nanoshells |
US6518747B2 (en) * | 2001-02-16 | 2003-02-11 | Quantum Design, Inc. | Method and apparatus for quantitative determination of accumulations of magnetic particles |
GB0812679D0 (en) * | 2008-07-10 | 2008-08-20 | Sec Dep For Innovation Universities | Sample carrier for effecting chemical assays |
JP5481326B2 (en) * | 2010-09-08 | 2014-04-23 | 株式会社日立製作所 | Measuring apparatus and measuring method using biomaterial detection element |
EP2634579B1 (en) * | 2012-03-03 | 2014-12-17 | Astrium GmbH | Method for performing immuno-assays in zero gravity |
WO2014007034A1 (en) * | 2012-07-06 | 2014-01-09 | 株式会社 日立ハイテクノロジーズ | Analysis device and analysis method |
CN103954664A (en) * | 2014-04-10 | 2014-07-30 | 深圳普门科技有限公司 | Electrode disk, preparation method thereof and electrochemical flow cell based on same |
US11673134B2 (en) * | 2017-06-06 | 2023-06-13 | Northwestern University | Trans-interfacial magnetic separation |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0030087A1 (en) * | 1979-11-13 | 1981-06-10 | Technicon Instruments Company Limited | Immunoassay method and apparatus and kit for carrying out the method |
US4431919A (en) * | 1980-04-10 | 1984-02-14 | U.S. Philips Corporation | Detection apparatus, particularly for use in liquid chromatography |
WO1986005815A1 (en) * | 1985-03-25 | 1986-10-09 | Genetics International Inc. | Nucleic acid sequences attached to materials sensitive to magnetic fields, and methods of assay and apparatus using such attached sequences. |
US4628037A (en) * | 1983-05-12 | 1986-12-09 | Advanced Magnetics, Inc. | Binding assays employing magnetic particles |
US4652533A (en) * | 1983-04-28 | 1987-03-24 | Pandex Laboratories, Inc. | Method of solid phase immunoassay incorporating a luminescent label |
WO1987006706A1 (en) * | 1986-04-30 | 1987-11-05 | Igen, Inc. | Electrochemiluminescent assays |
US5061445A (en) * | 1988-11-03 | 1991-10-29 | Igen, Inc. | Apparatus for conducting measurements of electrochemiluminescent phenomena |
US5068088A (en) * | 1988-11-03 | 1991-11-26 | Igen, Inc. | Method and apparatus for conducting electrochemiluminescent measurements |
US5093268A (en) * | 1988-04-28 | 1992-03-03 | Igen, Inc. | Apparatus for conducting a plurality of simultaneous measurements of electrochemiluminescent phenomena |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5238808A (en) * | 1984-10-31 | 1993-08-24 | Igen, Inc. | Luminescent metal chelate labels and means for detection |
-
1992
- 1992-02-04 IL IL10086692A patent/IL100866A/en not_active IP Right Cessation
- 1992-02-05 AU AU15304/92A patent/AU1530492A/en not_active Abandoned
- 1992-02-05 NZ NZ24153892A patent/NZ241538A/en not_active IP Right Cessation
- 1992-02-05 IE IE920381A patent/IE69371B1/en not_active IP Right Cessation
- 1992-02-05 JP JP4507261A patent/JP3013937B2/en not_active Expired - Lifetime
- 1992-02-05 WO PCT/US1992/000982 patent/WO1992014138A1/en active Application Filing
- 1992-02-07 CN CN 92101900 patent/CN1107863C/en not_active Expired - Lifetime
-
1998
- 1998-07-15 JP JP10233430A patent/JP3128541B2/en not_active Expired - Lifetime
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0030087A1 (en) * | 1979-11-13 | 1981-06-10 | Technicon Instruments Company Limited | Immunoassay method and apparatus and kit for carrying out the method |
US4431919A (en) * | 1980-04-10 | 1984-02-14 | U.S. Philips Corporation | Detection apparatus, particularly for use in liquid chromatography |
US4652533A (en) * | 1983-04-28 | 1987-03-24 | Pandex Laboratories, Inc. | Method of solid phase immunoassay incorporating a luminescent label |
US4628037A (en) * | 1983-05-12 | 1986-12-09 | Advanced Magnetics, Inc. | Binding assays employing magnetic particles |
WO1986005815A1 (en) * | 1985-03-25 | 1986-10-09 | Genetics International Inc. | Nucleic acid sequences attached to materials sensitive to magnetic fields, and methods of assay and apparatus using such attached sequences. |
WO1987006706A1 (en) * | 1986-04-30 | 1987-11-05 | Igen, Inc. | Electrochemiluminescent assays |
US5093268A (en) * | 1988-04-28 | 1992-03-03 | Igen, Inc. | Apparatus for conducting a plurality of simultaneous measurements of electrochemiluminescent phenomena |
US5061445A (en) * | 1988-11-03 | 1991-10-29 | Igen, Inc. | Apparatus for conducting measurements of electrochemiluminescent phenomena |
US5068088A (en) * | 1988-11-03 | 1991-11-26 | Igen, Inc. | Method and apparatus for conducting electrochemiluminescent measurements |
Non-Patent Citations (6)
Title |
---|
BIOCHEM. BIOPHYS. RES. COMM., Volume 128, No. 2, issued 30 April 1985, Y. IKARIYAMA et al., "Electrochemical Luminescence-Based Homogeneous Immunoassay", pages 987-992. * |
CLIN. CHEM., Volume 26, No. 6, issued 1980, M. POURFARZANEH et al., "Cortisol Directly Determinedin Serum by Fluoroimmunoassay with Magnetizable Solid Phase", pages 730-733. * |
CLIN. CHEM., Volume 26, No. 9, issued September 1980, R.S. KAMEL et al., "Magnetizable Solid Phase Fluoroimmunoassay of Phenyltoin in Disposable Test Tubes", pages 1881-1284. * |
CLIN. CHEM., Volume 37, No. 9, issued September 1991, J.H. KENTEN et al., "Rapid Electrochemiluminescence Assays of Polymerase Chain Reaction Products", pages 1626-1632. * |
J. ALLERGY AND CLIN. IMM., Volume 61, No. 1, issued January 1978, J.L. GUESDON et al., "Magnetic Enzyme Immunoassay for Measuring Human IGE", pages 23-27. * |
NUCLEIC ACIDS RESEARCH, Vol. 16, No. 11, issued 1988, M.S. URDEA et al., "A Comparison of Nonradioisotopichybridization Assay Methods Using Chemiluminescent and Enzyme Labeled Synthetic Oligodeoxyribonucleotide Probes", pages 4937-4956. * |
Cited By (105)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5720922A (en) * | 1993-05-14 | 1998-02-24 | Igen International, Inc. | Instrument incorporating electrochemiluminescent technology |
US5466416A (en) * | 1993-05-14 | 1995-11-14 | Ghaed; Ali | Apparatus and methods for carrying out electrochemiluminescence test measurements |
US5543112A (en) * | 1993-05-14 | 1996-08-06 | Igen, Inc. | Apparatus and methods for carrying out electrochemiluminescence test measurements |
US5624637A (en) * | 1993-05-14 | 1997-04-29 | Igen, Inc. | Apparatus and methods for carrying out electrochemiluminescence test measurements |
US5632956A (en) * | 1993-05-14 | 1997-05-27 | Igen, Inc. | Apparatus and methods for carrying out electrochemiluminescence test measurements |
US5700427A (en) * | 1993-05-14 | 1997-12-23 | Igen International, Inc. | Apparatus for carrying out electrochemiluminescence test measurements |
EP0871864A4 (en) * | 1994-11-10 | 1999-02-10 | Igen Inc | Magnetic particle based electrochemiluminescent detection apparatus and method |
US5744367A (en) * | 1994-11-10 | 1998-04-28 | Igen International, Inc. | Magnetic particle based electrochemiluminescent detection apparatus and method |
EP0871864A1 (en) * | 1994-11-10 | 1998-10-21 | Igen, Inc. | Magnetic particle based electrochemiluminescent detection apparatus and method |
US6133043A (en) * | 1994-11-10 | 2000-10-17 | Igen International, Inc. | Magnetic particle based electrochemiluminescent detection apparatus and method |
US5538687A (en) * | 1994-12-16 | 1996-07-23 | Behringer Mannheim Gmbh | Apparatus for generating optically detectable signals by applying electrical potentials to sample liquids |
US6846629B2 (en) | 1995-05-09 | 2005-01-25 | Mesoscale Technologies, Llc. | Methods and apparatus for improved luminescence assays using microparticles |
US6132955A (en) * | 1995-05-18 | 2000-10-17 | Igen International, Inc. | Method for derivitizing electrodes and assay methods using such derivitized electrodes |
EP0859230A1 (en) * | 1997-02-10 | 1998-08-19 | Cranfield University | Detection of analytes using electrochemistry |
EP0859229A1 (en) * | 1997-02-10 | 1998-08-19 | Gist-Brocades B.V. | Detection of analytes using electrochemistry |
US6100045A (en) * | 1997-02-10 | 2000-08-08 | Dsm N.V. | Detection of analytes using electrochemistry |
WO1998041867A1 (en) * | 1997-03-18 | 1998-09-24 | Igen International, Inc. | Detection of water-borne parasites using electrochemiluminescence |
US6146838A (en) * | 1997-03-18 | 2000-11-14 | Igen International, Inc. | Detecting water-borne parasites using electrochemiluminescence |
EP1042508A1 (en) * | 1997-12-23 | 2000-10-11 | Meso Scale Technologies LLC | Methods and apparatus for improved luminescence assays using microparticles |
EP2186910A3 (en) * | 1997-12-23 | 2011-04-06 | Meso Scale Technologies LLC | Methods and compositions for improved luminescence assays using microparticles |
EP1042508A4 (en) * | 1997-12-23 | 2002-05-29 | Meso Scale Technologies Llc | Methods and apparatus for improved luminescence assays using microparticles |
US9448235B2 (en) | 1997-12-23 | 2016-09-20 | Meso Scale Technologies Llc. | Methods and apparatus for improved luminescence assays using microparticles |
US6599473B1 (en) | 1998-01-30 | 2003-07-29 | Roche Diagnostics Gmbh | Electrochemilumiscence method for detecting analytes |
WO1999039206A1 (en) * | 1998-01-30 | 1999-08-05 | Roche Diagnostics Gmbh | Method for analyzing a test sample by means of an electro-chemoluminescence bond reaction test |
WO2000003233A1 (en) * | 1998-07-10 | 2000-01-20 | Imperial College Of Science, Technology And Medicine | Electrochemiluminescence cell with floating reaction electrodes |
US6696020B1 (en) | 1998-07-10 | 2004-02-24 | Imperial College Of Science, Technology And Medicine | Electrochemiluminescence cell with floating reaction electrodes |
US6136268A (en) * | 1999-08-17 | 2000-10-24 | Orion Diagnostica | Method for luminescence measurements |
EP1325333A1 (en) * | 2000-10-10 | 2003-07-09 | Aviva Biosciences Corporation | Individually addressable micro-electromagnetic unit array chips in horizontal configurations |
EP1325333A4 (en) * | 2000-10-10 | 2006-03-22 | Aviva Biosciences Corp | Individually addressable micro-electromagnetic unit array chips in horizontal configurations |
WO2003096014A3 (en) * | 2002-05-08 | 2004-03-04 | Yissum Res Dev Co | Magneto-controlled method and system for determining an analyte in a liquid medium |
WO2003096014A2 (en) * | 2002-05-08 | 2003-11-20 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Magneto-controlled method and system for determining an analyte in a liquid medium |
US10677695B2 (en) | 2002-11-07 | 2020-06-09 | Lsi Medience Corporation | Magnetic material for collecting magnetic particles and utilization thereof |
AT413153B (en) * | 2004-03-11 | 2005-11-15 | Christian Doppler Labor Fuer S | METHOD AND DEVICE FOR DETECTING MARKED MICROPARTICLES |
US9414777B2 (en) | 2004-07-13 | 2016-08-16 | Dexcom, Inc. | Transcutaneous analyte sensor |
US9986942B2 (en) | 2004-07-13 | 2018-06-05 | Dexcom, Inc. | Analyte sensor |
US11883164B2 (en) | 2004-07-13 | 2024-01-30 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US11064917B2 (en) | 2004-07-13 | 2021-07-20 | Dexcom, Inc. | Analyte sensor |
US11045120B2 (en) | 2004-07-13 | 2021-06-29 | Dexcom, Inc. | Analyte sensor |
US11026605B1 (en) | 2004-07-13 | 2021-06-08 | Dexcom, Inc. | Analyte sensor |
US10993642B2 (en) | 2004-07-13 | 2021-05-04 | Dexcom, Inc. | Analyte sensor |
US10993641B2 (en) | 2004-07-13 | 2021-05-04 | Dexcom, Inc. | Analyte sensor |
US10980452B2 (en) | 2004-07-13 | 2021-04-20 | Dexcom, Inc. | Analyte sensor |
US10932700B2 (en) | 2004-07-13 | 2021-03-02 | Dexcom, Inc. | Analyte sensor |
US10918314B2 (en) | 2004-07-13 | 2021-02-16 | Dexcom, Inc. | Analyte sensor |
US10918315B2 (en) | 2004-07-13 | 2021-02-16 | Dexcom, Inc. | Analyte sensor |
US10918313B2 (en) | 2004-07-13 | 2021-02-16 | Dexcom, Inc. | Analyte sensor |
US10827956B2 (en) | 2004-07-13 | 2020-11-10 | Dexcom, Inc. | Analyte sensor |
US10813576B2 (en) | 2004-07-13 | 2020-10-27 | Dexcom, Inc. | Analyte sensor |
US10799159B2 (en) | 2004-07-13 | 2020-10-13 | Dexcom, Inc. | Analyte sensor |
US10799158B2 (en) | 2004-07-13 | 2020-10-13 | Dexcom, Inc. | Analyte sensor |
US10722152B2 (en) | 2004-07-13 | 2020-07-28 | Dexcom, Inc. | Analyte sensor |
US10709363B2 (en) | 2004-07-13 | 2020-07-14 | Dexcom, Inc. | Analyte sensor |
US10709362B2 (en) | 2004-07-13 | 2020-07-14 | Dexcom, Inc. | Analyte sensor |
US10524703B2 (en) | 2004-07-13 | 2020-01-07 | Dexcom, Inc. | Transcutaneous analyte sensor |
US10918317B2 (en) | 2005-03-10 | 2021-02-16 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US10610136B2 (en) | 2005-03-10 | 2020-04-07 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US11051726B2 (en) | 2005-03-10 | 2021-07-06 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US11000213B2 (en) | 2005-03-10 | 2021-05-11 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US10925524B2 (en) | 2005-03-10 | 2021-02-23 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US10918316B2 (en) | 2005-03-10 | 2021-02-16 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US10918318B2 (en) | 2005-03-10 | 2021-02-16 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US10610135B2 (en) | 2005-03-10 | 2020-04-07 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US10610137B2 (en) | 2005-03-10 | 2020-04-07 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US10743801B2 (en) | 2005-03-10 | 2020-08-18 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US10617336B2 (en) | 2005-03-10 | 2020-04-14 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US10856787B2 (en) | 2005-03-10 | 2020-12-08 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US10898114B2 (en) | 2005-03-10 | 2021-01-26 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US10716498B2 (en) | 2005-03-10 | 2020-07-21 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US10709364B2 (en) | 2005-03-10 | 2020-07-14 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US10813577B2 (en) | 2005-06-21 | 2020-10-27 | Dexcom, Inc. | Analyte sensor |
WO2007101661A1 (en) | 2006-03-09 | 2007-09-13 | F.Hoffmann-La Roche Ag | Anti-drug antibody assay |
GB2436616A (en) * | 2006-03-29 | 2007-10-03 | Inverness Medical Switzerland | Assay device and method |
WO2008031532A1 (en) | 2006-09-12 | 2008-03-20 | F. Hoffmann-La Roche Ag | Anti-drug antibody assay |
EP2573562A3 (en) * | 2007-02-09 | 2013-10-30 | Advanced Liquid Logic, Inc. | Droplet actuator devices and methods employing magnetic beads |
US10379112B2 (en) | 2007-02-09 | 2019-08-13 | Advanced Liquid Logic, Inc. | Droplet actuator devices and methods employing magnetic beads |
WO2008104344A1 (en) | 2007-02-27 | 2008-09-04 | F. Hoffmann-La Roche Ag | Method for the assessment of the inhibitory activity of antibodies against insulin-like growth factor i receptor |
US8530176B2 (en) | 2007-12-15 | 2013-09-10 | Hoffmann-La Roche Inc. | Distinguishing assay |
US8227195B2 (en) | 2007-12-15 | 2012-07-24 | Hoffman-La Roche Inc. | Distinguishing assay |
EP2573568A1 (en) | 2007-12-15 | 2013-03-27 | F. Hoffmann-La Roche AG | Distinguishing assay |
WO2009077127A1 (en) | 2007-12-15 | 2009-06-25 | F. Hoffmann-La Roche Ag | Distinguishing assay |
WO2010072384A1 (en) | 2008-12-22 | 2010-07-01 | F. Hoffmann-La Roche Ag | ANTI-IDIOTYPE ANTIBODY AGAINST AN ANTIBODY AGAINST THE AMYLOID β PEPTIDE |
US8614297B2 (en) | 2008-12-22 | 2013-12-24 | Hoffmann-La Roche Inc. | Anti-idiotype antibody against an antibody against the amyloid β peptide |
WO2012022774A1 (en) | 2010-08-19 | 2012-02-23 | Roche Diagnostics Gmbh | An assay for measurement of antibodies binding to a therapeutic monoclonal antibody |
US9081016B2 (en) | 2010-08-19 | 2015-07-14 | Roche Diagnostics Operations, Inc. | Assay for measurement of antibodies binding to a therapeutic monoclonal antibody |
WO2012143380A1 (en) | 2011-04-20 | 2012-10-26 | F. Hoffmann-La Roche Ag | Microwaves for immunohistochemical analysis |
WO2012175508A1 (en) | 2011-06-22 | 2012-12-27 | F. Hoffmann-La Roche Ag | Removal of target cells by circulating virus-specific cytotoxic t-cells using mhc class i comprising complexes |
WO2013092611A2 (en) | 2011-12-19 | 2013-06-27 | F. Hoffmann - La Roche Ag | Method for the detection of free binding partner of a multispecific binder |
US10761097B2 (en) | 2012-02-01 | 2020-09-01 | Hoffmann-La Roche Inc. | Method for the detection of a binding partner of a multispecific binder |
WO2013113663A1 (en) | 2012-02-01 | 2013-08-08 | F. Hoffmann-La Roche Ag | Method for the detection of a binding partner of a multispecific binder |
US9945869B2 (en) | 2012-02-01 | 2018-04-17 | Hoffmann-La Roche Inc. | Method for the detection of a binding partner of a multispecific binder |
WO2013132000A1 (en) | 2012-03-08 | 2013-09-12 | F. Hoffmann-La Roche Ag | Multiplexed chromatography-immunoassay method for the characterization of circulating immune complexes |
WO2014009474A1 (en) | 2012-07-13 | 2014-01-16 | F. Hoffmann-La Roche Ag | Method for the detection of a multispecific binder |
US10501521B2 (en) | 2012-12-21 | 2019-12-10 | Hoffmann-La Roche Inc. | Disulfide-linked multivalent MHC class I comprising multi-function proteins |
WO2015000865A1 (en) | 2013-07-04 | 2015-01-08 | F. Hoffmann-La Roche Ag | Interference-suppressed immunoassay to detect anti-drug antibodies in serum samples |
WO2017072210A1 (en) | 2015-10-29 | 2017-05-04 | F. Hoffmann-La Roche Ag | Anti-variant fc-region antibodies and methods of use |
WO2017093226A1 (en) | 2015-11-30 | 2017-06-08 | F. Hoffmann-La Roche Ag | Immunoassay for the determination of fc-region modified antibodies |
WO2019105916A1 (en) | 2017-11-29 | 2019-06-06 | F. Hoffmann-La Roche Ag | Target interference suppressed anti-drug antibody assay |
WO2020141145A1 (en) | 2018-12-30 | 2020-07-09 | F. Hoffmann-La Roche Ag | Anti-rabbit cd19 antibodies and methods of use |
WO2020229378A1 (en) | 2019-05-13 | 2020-11-19 | F. Hoffmann-La Roche Ag | Interference-suppressed pharmacokinetic immunoassay |
WO2021136772A1 (en) | 2020-01-02 | 2021-07-08 | F. Hoffmann-La Roche Ag | Method for determining the amount of a therapeutic antibody in the brain |
WO2021254926A1 (en) | 2020-06-16 | 2021-12-23 | F. Hoffmann-La Roche Ag | Method for determining the free antigen of an antibody in a sample |
WO2022214565A1 (en) | 2021-04-09 | 2022-10-13 | F. Hoffmann-La Roche Ag | Process for selecting cell clones expressing a heterologous polypeptide |
WO2023021055A1 (en) | 2021-08-19 | 2023-02-23 | F. Hoffmann-La Roche Ag | Multivalent anti-variant fc-region antibodies and methods of use |
WO2023117325A1 (en) | 2021-12-21 | 2023-06-29 | F. Hoffmann-La Roche Ag | Method for the determination of hydrolytic activity |
WO2024044622A1 (en) | 2022-08-24 | 2024-02-29 | Amgen Inc. | Anti-drug antibody assays |
Also Published As
Publication number | Publication date |
---|---|
JPH11125601A (en) | 1999-05-11 |
AU1530492A (en) | 1992-09-07 |
IE69371B1 (en) | 1996-09-04 |
CN1065339A (en) | 1992-10-14 |
JP3013937B2 (en) | 2000-02-28 |
NZ241538A (en) | 1993-02-25 |
IL100866A (en) | 1995-10-31 |
CN1107863C (en) | 2003-05-07 |
IE920381A1 (en) | 1992-08-12 |
JP3128541B2 (en) | 2001-01-29 |
JPH06508203A (en) | 1994-09-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5705402A (en) | Method and apparatus for magnetic microparticulate based luminescence assay including plurality of magnets | |
EP0570518B1 (en) | Methods and apparatus for improved electrochemi-luminescence assays | |
US5935779A (en) | Methods for improved particle electrochemiluminescence assay | |
WO1992014138A1 (en) | Method and apparatus for magnetic microparticulate based luminescence assay including plurality of magnets | |
US6325973B1 (en) | Methods and apparatus for improved luminescence assays | |
US5779976A (en) | Apparatus for improved luminescence assays | |
US5962218A (en) | Methods and apparatus for improved luminescence assays | |
AU637775B2 (en) | Electrochemiluminescent assays | |
US5746974A (en) | Apparatus for improved luminescence assays using particle concentration, electrochemical generation of chemiluminescence and chemiluminescence detection | |
EP0594766B1 (en) | Methods for improved luminescence assays using particle concentration and chemiluminescence detection | |
US5770459A (en) | Methods and apparatus for improved luminescence assays using particle concentration, electrochemical generation of chemiluminescence detection | |
US6881589B1 (en) | Electrochemiluminescent localizable complexes for assay compositions | |
US7462322B2 (en) | Methods and apparatus for improved luminescence assays | |
AU676665C (en) | Methods and apparatus for improved luminescence assays usingparticle concentration and chemiluminescence detection |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AT AU BB BG BR CA CH DE DK ES FI GB HU JP KP KR LK LU MG MW NL NO PL RO RU SD SE |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE BF BJ CF CG CH CI CM DE DK ES FR GA GB GN GR IT LU MC ML MR NL SE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: CA |